Document:

EX-10.48

 Exhibit 10.48 

***Text Omitted and Filed Separately with the Securities and Exchange Commission. 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
 Execution Version 

November 18, 2013 
 AstraZeneca AB 

SE-431 83 
 Mölndal 

Sweden 
 Attn: President 

POZEN Inc. 
 1414 Raleigh Road, Suite 400 

Chapel Hill, North Carolina 27517 
 U.S.A 

Attn: President and Chief Executive Officer 
 Re:
Acknowledgements and agreements regarding rights and responsibilities of the parties in relation to the License Agreements 
 Ladies and Gentlemen: 

As you are aware, AstraZeneca AB, a corporation organized under the laws of Sweden (“AstraZeneca”) and Horizon Pharma U.S.A, Inc., a
corporation organized under the laws of Delaware (“Horizon”) have, on the date of this letter agreement, executed that certain Asset Purchase Agreement by and between AstraZeneca and Horizon (the “APA”) pursuant to
which AstraZeneca has agreed, subject to the terms and conditions of the APA, to transfer, assign and license to Horizon all rights of AstraZeneca and its affiliates to Vimovo® and other
pharmaceutical products that contain gastroprotective agents in a single fixed combination oral solid dosage form with non-steroidal anti-inflammatory drugs in the United States and its territories and possessions (the “U.S.”),
including, without limitation, all licenses and other rights granted to AstraZeneca by POZEN, Inc. (“POZEN”) with respect to such products in the U.S. (the “Divestiture”). 

The parties acknowledge that, as of the date of this letter agreement, AstraZeneca and POZEN are parties to that certain Collaboration and License Agreement,
dated August 1, 2006, by and between AstraZeneca and POZEN, as amended prior to the date of this letter agreement (the “Original License Agreement”). In order to facilitate the transactions contemplated by the APA, AstraZeneca
and POZEN have, on the date of this letter agreement, amended and restated the Original License Agreement in two separate agreements, each of which shall become effective on the closing of the APA: (i) that certain Amended and Restated
Collaboration and License Agreement for the United States, by and between AstraZeneca and POZEN (as may be amended in accordance with its terms, the “U.S. License Agreement”), which sets forth all rights and obligations as between
AstraZeneca and POZEN with respect to Products (as defined below) in the U.S., and (ii) that certain Amended and Restated Collaboration and License Agreement, by and between AstraZeneca and POZEN (as

  
 1 

 
may be amended in accordance with its terms, the “ROW License Agreement”), which sets forth all rights and obligations as between AstraZeneca and POZEN with respect to Products
(as defined below) outside the U.S. Pursuant to the APA, AstraZeneca has agreed, among other things, to assign to Horizon, and Horizon has agreed to assume, the U.S. License Agreement effective on the closing of the transactions contemplated under
the APA. The date on which such closing occurs is referred to as the “Transfer Date.” 
 The parties are executing this letter agreement to
(i) facilitate the transactions contemplated by the APA with respect to the assignment by AstraZeneca, and assumption by Horizon, of the U.S. License Agreement, and (ii) acknowledge and agree to certain matters relating to the rights,
obligations and liabilities of the parties in relation to the Original License Agreement, the U.S. License Agreement and the ROW License Agreement. 
 In
consideration of the foregoing, the parties acknowledge and agree to the following: 
 1. Definitions. For purposes of this
letter agreement, the following terms are defined as indicated: 
 “Affiliate” means a legal entity that, directly or
indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with an entity. For purposes of this definition only, “control” and, with correlative meanings, the terms “controlled by” and
“under common control with” means (a) the possession, directly or indirectly, of the power to direct the management or policies of a legal entity, whether through the ownership of voting securities or by contract relating to voting
rights or corporate governance, or (b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a legal entity; provided, that if local law restricts foreign ownership, control will be
established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. 

“AstraZeneca Territory” means worldwide, excluding the Horizon Territory and Japan. 

“AstraZeneca Net Sales” means Net Sales as defined in the ROW License Agreement. 

“Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 and December 31. 
 “Esomeprazole” means that certain
pharmaceutical compound with the name (5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole), including any [...***...]. 

“Field of Use” means the treatment of human diseases and conditions by means of a pharmaceutical product. 

“Horizon Territory” means the United States and its territories and possessions. 

“Horizon Net Sales” means Net Sales as defined in the U.S. License Agreement. 

  
  

	***	Confidential Treatment Requested 

  

2 

 “Licensed Technology” has the meaning set forth in (a) for purposes of
paragraph 7(a) below, the U.S. License Agreement and (b) for purposes of paragraph 7(d) below, the ROW License Agreement. 

“Milestone Event” means an event set forth in the table in paragraph 5 below. 

“Milestone Payment” means a payment set forth in the table in paragraph 5 below. 

“Milestone Share” means (a) with respect to AstraZeneca, (i) the applicable Milestone Payment multiplied by
(ii) a fraction, the numerator of which is the AstraZeneca Net Sales for the applicable calendar year, and the denominator of which is the sum of (A) the AstraZeneca Net Sales for such calendar year and (B) the Horizon Net Sales for
such calendar year; and (b) with respect to Horizon, (i) the applicable Milestone Payment multiplied by (ii) a fraction, the numerator of which is the Horizon Net Sales for the applicable calendar year, and the denominator of which is
the sum of (A) the Horizon Net Sales for such calendar year and (B) the AstraZeneca Net Sales for such calendar year. 

“Nexium” means AstraZeneca AB’s and its Affiliates’ products containing Esomeprazole as the sole active ingredient
in any presentation form. 
 “Nexium Business” means AstraZeneca AB’s and its Affiliates’ development and
commercialization activities pertaining to Esomeprazole and Esomeprazole based products. 
 “ROW Licensed Patents” means
Licensed Patents as defined in the ROW License Agreement. 
 “Products” has the meaning set forth in (a) with respect
to references in this letter agreement to development, manufacture, commercialization or other exploitation of Products in the AstraZeneca Territory, the ROW License Agreement and (b) with respect to references in this letter agreement to
development, manufacture, commercialization or other exploitation of Products in the Horizon Territory, the U.S. License Agreement. 

“Sublicensees” has the meaning set forth in (a) for purposes of paragraph 7(a) below, except as otherwise expressly
provided in paragraph 7(a) below, the ROW License Agreement and (b) for purposes of paragraph 7(d) below, except as otherwise expressly provided in paragraph 7(d) below, the U.S. License Agreement. 

“Supply Agreement” means that certain supply agreement to be entered into by Horizon and AstraZeneca LP in connection with
the Divestiture pursuant to which AstraZeneca LP will supply Horizon with Vimovo® until December 31, 2014. 

“US Licensed Patents” means Licensed Patents as defined in the U.S. License Agreement. 

2. Consent to Assignment of U.S. License Agreement, Joint Inventions and Joint Patents. POZEN hereby consents to the assignment
by AstraZeneca, and assumption by 

  
 3 

 Horizon, of the U.S. License Agreement and all of AstraZeneca’s and its Affiliates’ right, title and
interest in and to the Joint Inventions (as defined in the Original License Agreement) and Joint Patents (as defined in the Original License Agreement) in the Horizon Territory conceived under the Original Agreement, in each case, effective as of
the Transfer Date. Each of POZEN and AstraZeneca hereby represents and warrants to Horizon as of the date hereof that the Original License Agreement is in full force and effect. 

3. Assumption of Transferred Rights and Obligations. Pursuant to the APA, effective as of the Transfer Date, Horizon will assume
and accept all rights, liabilities and obligations of AstraZeneca under the U.S. License Agreement arising on or after the Transfer Date. All rights, liabilities and obligations of AstraZeneca with respect to POZEN other than those transferred to
Horizon in connection with the Divestiture, will remain rights, liabilities and obligations of AstraZeneca. The foregoing does not modify the agreements as between AstraZeneca and POZEN set forth in the side letter agreement between AstraZeneca and
POZEN dated September 16, 2013. 
 4. Release of Liabilities. The parties hereby agree that Horizon will not be
responsible for, and POZEN, on behalf of itself and its Affiliates and its and their respective successors and assigns, officers, employees and directors and any third parties claiming through POZEN (collectively, the “Releasors”),
hereby releases and forever discharges Horizon, its Affiliates and its and their respective successors and assigns, and the shareholders, officers, directors, employees, agents, trustees and beneficiaries of each of the foregoing (each individually,
a “Horizon Party”) of and from, any and all claims, suits, acts, damages, demands, liabilities, rights of action and causes of action, both in law and equity, whether known or unknown, foreseen or unforeseen, matured or contingent,
that the Releasors ever had, now have, or in the future may have against any Horizon Party arising out of or directly related to the Original License Agreement, including matters arising after the Transfer Date that arise out of or directly relate
to the Original License Agreement (the “Claims”). Furthermore, POZEN, on behalf of itself and its respective Releasors, agrees not to sue, or otherwise institute or cause to be instituted, or in any way voluntarily participate in,
assist in (financially or otherwise) or authorize the prosecution of any Claim against any Horizon Party in any federal, state, local or other court, or in any other forum. 

5. Sales Milestones. 

a. If any Milestone Event is achieved during the term of either the U.S. License Agreement or ROW License Agreement, each of AstraZeneca and
Horizon shall pay to POZEN directly its Milestone Share (if any) with respect to the applicable Milestone Event within [...***...] ([...***...]) [...***...] following the achievement of such Milestone Event. AstraZeneca shall not be
liable for Horizon’s failure to pay Horizon’s Milestone Share to POZEN, and Horizon shall not be liable for AstraZeneca’s failure to pay AstraZeneca’s Milestone Share to POZEN. 

  
  

	***	Confidential Treatment Requested 

  

4 

			
	 Milestone Event
	  	 Milestone Payment

		
	 1.      End of first calendar year during which aggregate annual Horizon Net Sales and AstraZeneca
Net Sales were at least $550,000,000
	  	$[...***...]
		
	 2.      End of first calendar year during which aggregate annual Horizon Net Sales and AstraZeneca
Net Sales were at least $[...***...]
	  	$[...***...]
		
	 3.      End of first calendar year during which aggregate annual Horizon Net Sales and AstraZeneca
Net Sales were at least $[...***...]
	  	$[...***...]
		
	 4.      End of first calendar year during which aggregate annual Horizon Net Sales and AstraZeneca
Net Sales were at least $1,250,000,000
	  	$[...***...]

 Each Milestone Payment shall be payable only once, and not for each time that the applicable Milestone Event is achieved. 

b. Until each Milestone Event has been achieved, AstraZeneca shall provide Horizon a copy of each report AstraZeneca provides to POZEN under
Section 8.3.1 of the ROW License Agreement. AstraZeneca shall provide such copies to Horizon within [...***...] ([...***...]) [...***...] after the end of the applicable Calendar Quarter with respect to the first
(1st) three (3) Calendar Quarters of a calendar year and within [...***...] ([...***...]) [...***...] after the end of the fourth Calendar Quarter of the applicable calendar year. 

c. Until each Milestone Event has been achieved, Horizon shall provide AstraZeneca a copy of each report Horizon provides to POZEN under
Section 8.2.1 of the U.S. License Agreement. Horizon shall provide such copies to AstraZeneca within 
 [...***...] ([...***...])
[...***...] after the end of the applicable Calendar Quarter with respect to the first (1st) three (3) Calendar Quarters of a calendar year and within [...***...] ([...***...]) [...***...] after the end of the
fourth Calendar Quarter of the applicable calendar year. 
 d. Until each Milestone Event has been achieved, promptly after receipt by each
of Horizon and AstraZeneca of the reports described in the immediately preceding two paragraphs, and in any event no later than [...***...] ([...***...]) [...***...] after the end of the fourth Calendar Quarter of the applicable
calendar year, AstraZeneca and Horizon shall confer regarding whether a Milestone Event has been achieved during the preceding calendar year and, if so, the Milestone Share payable by each of Horizon and AstraZeneca for the achievement of any such
Milestone Event. [...***...] and [...***...] of [...***...] and [...***...] to [...***...] in an [...***...], and [...***...] of [...***...] and in the [...***...]

  
  

	***	Confidential Treatment Requested 

  

5 

 
[...***...]. For clarity, this paragraph shall not limit either AstraZeneca’s or Horizon’s obligation to pay its respective Milestone Share when due. 

e. AstraZeneca shall not be responsible for failure to pay its Milestone Share for achievement of a Milestone Event when due, and such failure
shall not be deemed a breach of this letter agreement by AstraZeneca, to the extent such failure is the result of Horizon failing to timely report Horizon Net Sales to AstraZeneca in accordance with this letter agreement. Horizon shall not be
responsible for failure to pay its Milestone Share for achievement of a Milestone Event when due, and such failure shall not be deemed a breach of this letter agreement by Horizon, to the extent such failure is the result of AstraZeneca failing to
timely report AstraZeneca Net Sales to Horizon in accordance with this letter agreement. 
 f. The terms and conditions of
Section 8.3.3, Section 8.3.4, Section 8.3.5 and Section 8.5 of the ROW License Agreement shall apply with respect to any Milestone Share of AstraZeneca and the terms and conditions of Section 8.2.3, Section 8.2.4,
Section 8.2.5 and Section 8.4 of the U.S. License Agreement shall apply with respect to any Milestone Share of Horizon. 
 g. For
clarity, in the event the ROW Agreement or U.S. Agreement is terminated, AstraZeneca or Horizon, respectively, will (i) continue to provide reports to the other party as described above with respect to AstraZeneca Net Sales and Horizon Net
Sales, respectively, to the extent any AstraZeneca Net Sales and Horizon Net Sales, respectively, are achieved after such termination, and (ii) be obligated to pay its Milestone Share with respect to any Milestone Event achieved during an
applicable calendar year following such termination based on AstraZeneca Net Sales and Horizon Net Sales achieved during such calendar year. 

6. Transition Payments; [...***...]. Beginning on the Transfer Date, and continuing for a period ending on the later of (i) 

[...***...] ([...***...]) [...***...] thereafter, and (ii) the date on which [...***...], AstraZeneca acknowledges and agrees to
the following: 
 a. As part of its reporting obligations under Section 8.3.1 of the ROW Agreement, AstraZeneca will include in its
report provided to POZEN within [...***...] ([...***...]) of the end of the fourth (4th) Calendar Quarter of each year a summary profit and loss statement relating to VIMOVO [...***...], which will include [...***...].

 b. AstraZeneca will pay to POZEN, or credit against royalties otherwise payable by AstraZeneca to POZEN under the ROW License Agreement,
[...***...]% of any [...***...]; provided, that if for any reason there are no longer royalties payable by AstraZeneca under the ROW License Agreement, then POZEN will pay to AstraZeneca any amount that would otherwise be credited
against such royalties. 
 c. AstraZeneca will make any royalty payments to POZEN or take any credit due under this paragraph 6 in accordance
with Article 8 of the ROW License Agreement. 

  
  

	***	Confidential Treatment Requested 

  

6 

 7. Ex-Territory Sublicenses Under U.S. and ROW License Agreements; Supply Agreement
Sublicense. 
 a. Horizon hereby grants to AstraZeneca, effective as of the Transfer Date, a non-exclusive, royalty-free sublicense,
with the right to grant sublicenses through multiple tiers solely to Sublicensees, under the Licensed Technology to develop, make and have made (but not market, sell or otherwise commercialize) Products in the Field of Use in the Horizon Territory
solely in support of the development, commercialization or other exploitation of the Products in the Field of Use in the AstraZeneca Territory. If the U.S. License Agreement is terminated or otherwise ceases to be in effect for any reason other than
expiration thereof pursuant to its terms, then POZEN shall and does hereby automatically and without any additional consideration grant to AstraZeneca, with effect from the effective date of the termination of the U.S. License Agreement, a direct
non-exclusive, royalty-free license, with the right to grant sublicenses pursuant to Section 7.3 of the ROW License Agreement, under the Licensed Technology to develop, make and have made (but not market, sell or otherwise commercialize)
Products in the Field of Use in the Horizon Territory solely in support of the development, commercialization or other exploitation of the Products in the Field of Use in the AstraZeneca Territory, and such direct license shall continue in effect
for the duration of the ROW License Agreement. 
 b. Each of AstraZeneca and Horizon represents and warrants to POZEN as of the date hereof
that under the Supply Agreement Horizon grants AstraZeneca LP a non-exclusive, royalty-free, non-transferable (except in connection with a permitted assignment of the Supply Agreement pursuant to its terms) license under the Licensed Technology,
with the right to grant further sublicenses, to the extent necessary for AstraZeneca and its Affiliates to perform their obligations under the Supply Agreement. 

c. POZEN hereby consents to the sublicense granted by Horizon to AstraZeneca under paragraph 7(a) and the sublicense granted by Horizon to
AstraZeneca LP under the Supply Agreement as described in paragraph 7(b) and acknowledges and agrees that the provisions of Section 7.3 of the U.S. License Agreement shall not apply with respect to either sublicense (including any obligation to
guarantee performance of AstraZeneca or AstraZeneca LP as a sublicensee), neither AstraZeneca nor AstraZeneca LP shall be deemed to be a Sublicensee (as defined in the U.S. License Agreement) under the U.S. License Agreement and Horizon shall not be
responsible to POZEN for compliance by AstraZeneca or AstraZeneca LP with the terms of the U.S. License Agreement with respect to AstraZeneca’s exercise of the sublicense granted herein or AstraZeneca LP’s exercise of the sublicense
granted under the Supply Agreement, as applicable. 
 d. AstraZeneca hereby grants to Horizon, effective as of the Transfer Date, a
non-exclusive, royalty-free sublicense, with the right to grant sublicenses through multiple tiers solely to Sublicensees, under the Licensed Technology to develop, make and have made (but not market, sell or otherwise commercialize) Products in the
Field of Use in the AstraZeneca Territory solely in support of the development, commercialization or other exploitation of the Products in the Field of Use in the Horizon Territory. POZEN hereby consents to such sublicense and acknowledges and
agrees that the provisions of Section 7.3 of the ROW License 

  
 7 

 Agreement shall not apply with respect to such sublicense (including any obligation to guarantee performance of
Horizon as a sublicensee), Horizon shall not be deemed to be a Sublicensee (as defined in the ROW License Agreement) under the ROW License Agreement and AstraZeneca shall not be responsible to POZEN for compliance by Horizon with the terms of the
ROW License Agreement with respect to Horizon’s exercise of the sublicense granted herein. If the ROW License Agreement is terminated or otherwise ceases to be in effect for any reason other than expiration thereof pursuant to its terms, then
POZEN shall and does hereby automatically and without any additional consideration grant to Horizon, with effect from the effective date of the termination of the ROW License Agreement, a direct non-exclusive, royalty-free license, with the right to
grant sublicenses pursuant to Section 7.3 of the U.S. License Agreement, under the Licensed Technology to develop, make and have made (but not market, sell or otherwise commercialize) Products in the Field of Use in the AstraZeneca Territory
solely in support of the development, commercialization or other exploitation of the Products in the Field of Use in the Horizon Territory, and such direct license shall continue in effect for the duration of the U.S. License Agreement. 

8. Patent Prosecution Information.  

a. The parties acknowledge and agree that (i) in connection with the prosecution and maintenance of the US Licensed Patents pursuant to
the U.S. License Agreement it may be necessary or useful for the prosecuting and maintaining party to access the prosecution histories of the ROW Licensed Patents and any other information with respect to the prosecution of the ROW Licensed Patents
that is necessary or useful for the prosecution or maintenance of the US Licensed Patents pursuant to the U.S. License Agreement, (ii) notwithstanding any provision in the ROW License Agreement to the contrary, such prosecuting and maintaining
party shall have the right, at its sole expense, to obtain copies of such prosecution histories and other information solely for use in connection with the prosecution and maintenance of the US Licensed Patents under the U.S. License Agreement and
(iii) any information disclosed under this paragraph 8(a) shall be deemed Confidential Information (as defined in the U.S. License Agreement) of POZEN and subject to the provisions of Article 11 of the U.S. License Agreement, provided that such
prosecuting and maintaining party may disclose such Confidential Information to any patent authorities in the Horizon Territory to the extent such disclosure is made in connection with the performance of the U.S. License Agreement. 

b. The parties acknowledge and agree that (i) in connection with the prosecution and maintenance of the ROW Licensed Patents pursuant to
the ROW License Agreement it may be necessary or useful for the prosecuting and maintaining party to access the prosecution histories of the US Licensed Patents and any other information with respect to the prosecution of the US Licensed Patents
that is necessary or useful for the prosecution or maintenance of the ROW Licensed Patents pursuant to the ROW License Agreement, (ii) notwithstanding any provision in the U.S. License Agreement to the contrary, such prosecuting and maintaining
party shall have the right, at its sole expense, to obtain copies of such prosecution histories and other information solely for use in connection with the prosecution and maintenance of the ROW Licensed Patents under the ROW License Agreement and
(iii) any information disclosed under this paragraph 8(b) shall be deemed Confidential Information (as defined in the ROW License Agreement) of POZEN and subject to the provisions of Article 11 

  
 8 

 of the ROW License Agreement, provided that such prosecuting and maintaining party may disclose such Confidential
Information to any patent authorities in the AstraZeneca Territory to the extent such disclosure is made in connection with the performance of the ROW License Agreement. 

9. [...***...]. 
 a.
Capitalized terms used in this paragraph 9 but not defined in this letter agreement shall have the meaning set forth in the U.S. License Agreement. 

b. If POZEN is required by Applicable Law to provide to a Regulatory Authority in the [...***...] any communication that relates to
[...***...] and [...***...] as it [...***...], that [...***...] to [...***...]. 
 c. Except as otherwise set
forth in the U.S. License Agreement or ROW License Agreement or to comply with Applicable Law, [...***...] or [...***...] the [...***...]. 

d. If POZEN is required by Applicable Law to make any statements in an AE or SAE report in the [...***...] pertaining to
[...***...] of [...***...] and [...***...] the [...***...] to [...***...]. 
 e. POZEN is not by the U.S.
License Agreement, by implication or otherwise, granted any license or other right relating to [...***...] to [...***...] or [...***...] to [...***...] or [...***...]. 

f. Notwithstanding anything to the contrary in the U.S. License Agreement, [...***...] of [...***...] or [...***...] of its

 [...***...] or [...***...] of the [...***...]. 

  
  

	***	Confidential Treatment Requested 

  

9 

 g. Except as provided in paragraphs 9(b) or 9(d) above, without [...***...] prior written
consent, [...***...] will not make, and will prohibit its Affiliates, third party contractors, and agents from [...***...] or [...***...]. 

h. [...***...] in the [...***...] that is [...***...] and [...***...] the [...***...] the [...***...] that
[...***...] in the 
 [...***...] to be [...***...]. 

i. [...***...] to the [...***...]. 

10. Payment of U.S. Royalties During Transition Period. POZEN acknowledges and agrees that notwithstanding the assignment of the
U.S. License Agreement by AstraZeneca to Horizon as of the Transfer Date, AstraZeneca shall continue to be responsible for paying POZEN any royalties that are payable under the U.S. License Agreement with respect to any Net Sales (as defined in the
U.S. License Agreement) of any Product in the Horizon Territory during the period that begins on the Transfer Date and ends on December 31, 2013 and providing POZEN the corresponding sales reports required under the U.S. License Agreement with
respect to such period, and POZEN shall accept such amounts from AstraZeneca in satisfaction of Horizon’s obligations with respect thereto under the U.S. License Agreement. 

11. Assignment. 
 a.
AstraZeneca shall not sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this letter agreement or any of its rights or duties hereunder other than in connection
with a permitted assignment of the ROW License Agreement or any of its rights or duties thereunder pursuant to the terms thereof (an “AstraZeneca Permitted Assignment”). In the event of an AstraZeneca Permitted Assignment, this
letter agreement, and AstraZeneca’s rights and obligations hereunder, shall be automatically assigned to the assignee of AstraZeneca’s rights and duties under the ROW License Agreement. 

b. Horizon shall not sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law
or otherwise, this letter agreement or any of its rights or duties hereunder other than in connection with a permitted assignment of the U.S. License Agreement or any of its rights or duties thereunder pursuant to the terms thereof (a
“Horizon Permitted Assignment”). In the event of a Horizon Permitted Assignment, this letter agreement, and Horizon’s rights and obligations hereunder, shall be 

  
  

	***	Confidential Treatment Requested 

  

10 

 automatically assigned to the assignee of Horizon’s rights and duties under the U.S. License Agreement. 

c. POZEN shall not sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or
otherwise, this letter agreement or (i) its rights or duties hereunder with respect to AstraZeneca’s Milestone Share (paragraph 5) or Horizon’s sublicense to AstraZeneca (paragraph 7(a)), (ii) its duties hereunder with respect to
patent prosecution information for the ROW Licensed Patent (paragraph 8(a)) and (iii) its rights hereunder with respect to patent prosecution information for the US Licensed Patents (paragraph 8(b)) (collectively, the “POZEN ROW
Provisions”) other than in connection with a permitted assignment of the ROW License Agreement or any of its rights or duties thereunder pursuant to Section 15.1 thereof (a “POZEN Permitted ROW Assignment”). In the
event of a POZEN Permitted ROW Assignment, this letter agreement and POZEN’s rights and obligations under the POZEN ROW Provisions shall be automatically assigned to the assignee of POZEN’s rights and duties under the ROW License
Agreement. 
 d. POZEN shall not sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by
operation of law or otherwise, this letter agreement or (i) its rights or duties under paragraph 2 or paragraph 4, (ii) its rights or duties hereunder with respect to Horizon’s Milestone Share (paragraph 5), AstraZeneca’s
sublicense to Horizon (paragraph 7(d)), or the Nexium-related restrictions (paragraph 9), (iii) its rights hereunder with respect to patent prosecution information for the ROW Licensed Patent (paragraph 8(a)) and (iv) its duties hereunder
with respect to patent prosecution information for the US Licensed Patents (paragraph 8(b)) (collectively, the “POZEN US Provisions”) other than in connection with a permitted assignment of the U.S. License Agreement or any of its
rights or duties thereunder pursuant to Section 15.1 thereof (a “POZEN Permitted US Assignment”). In the event of a POZEN Permitted US Assignment, this letter agreement and POZEN’s rights and obligations under the POZEN US
Provisions shall be automatically assigned to the assignee of POZEN’s rights and duties under the U.S. License Agreement. For clarity, in no event will any sale, transfer, assignment, delegation, pledge or other disposal of the POZEN US
Provisions relieve POZEN of its agreements and duties under paragraph 4. 
 12. Representation of AstraZeneca. AstraZeneca
represents and warrants to POZEN as of the date hereof that pursuant to the APA AstraZeneca provides Horizon the representation and warranty set forth on Attachment A, and such representation and warranty is true and accurate in all material
respects as of the date hereof. 
 13. Miscellaneous. 

a. With respect to the rights and obligations of AstraZeneca and POZEN with respect to the POZEN ROW Provisions, this letter agreement is
subject to Articles 11 through 14 of the ROW License Agreement. With respect to the rights and obligations of Horizon and POZEN with respect to the POZEN US Provisions, this letter agreement is subject to Articles 11 through 14 of the U.S. License
Agreement. Any breach of this letter agreement by AstraZeneca or POZEN with respect to the POZEN ROW Provisions shall be deemed a breach of the ROW License Agreement by such party and subject to such parties’ respective rights and 

  
 11 

 remedies (and any applicable limitations) thereunder. Any breach of this letter agreement by Horizon or POZEN
with respect to the POZEN US Provisions shall be deemed a breach of the U.S. License Agreement by such party and subject to such parties’ respective rights and remedies (and any applicable limitations) thereunder. This letter agreement
automatically shall terminate with respect to AstraZeneca and POZEN with respect to the POZEN ROW Provisions upon the termination of the ROW License Agreement (subject to Sections 12.10 thereof). This letter agreement automatically shall terminate
with respect to Horizon and POZEN with respect to the POZEN US Provisions upon the termination of the U.S. License Agreement (subject to Sections 12.9 thereof). For clarity, the consent under paragraph 2, and the release and other agreements of
POZEN under paragraph 4, will survive any expiration or termination of this letter agreement. 
 b. Each of AstraZeneca, POZEN and Horizon
acknowledges and agrees that the terms of this letter agreement shall not become effective until the Transfer Date. 
 c. The agreements set
forth in this letter agreement are being relied upon by each of AstraZeneca and Horizon in connection with its determination to execute the APA. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of
this letter agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties hereto shall be entitled to an injunction or injunctions to prevent breaches of this letter
agreement and to enforce specifically the terms and provisions of this letter agreement in any court of the U.S. or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity. Each party
hereto hereby waives (i) any requirement that the other party post a bond or other security as a condition for obtaining any such relief, and (ii) any defenses in any action for specific performance, including the defense that a remedy at
law would be adequate. 
 d. This letter agreement shall be governed by and construed in accordance with the laws of the State of New York
applicable to contracts executed and performed in such state, without giving effect to the conflicts of laws principles thereof to the extent such principles would require or permit the application of the laws of another state. This letter agreement
may be executed in multiple counterparts, all of which taken together shall constitute a single instrument. Delivery of an executed counterpart of a signature page of this letter agreement by facsimile or other electronic transmission shall be
effective as delivery of a manually executed original counterpart of this letter agreement. No amendment or modification of this letter agreement will be binding upon the parties unless in writing and duly executed by authorized representatives of
AstraZeneca, Horizon and POZEN. 
 Please confirm the agreement of AstraZeneca and POZEN with the terms of this letter agreement by countersigning in the
space provided below. This letter agreement, once fully executed by AstraZeneca and POZEN, shall be deemed to have been executed as of the date first above written. 

-Signature page to follow- 

  
 12 

			
	Sincerely,
	
	Horizon Pharma U.S.A, Inc.
		
	By:	 	/s/ Timothy P. Walbert
	Name:	 	Timothy P. Walbert
	Title:	 	President and Chief Executive Officer

  

			
	Acknowledged and Agreed:
	
	AstraZeneca AB
		
	By:	 	/s/ Jan-Olof Jacke
	Name:	 	Jan-Olof Jacke
	Title:	 	President
	
	POZEN, Inc.
		
	By:	 	/s/ John R. Plachetka
	Name:	 	John R. Plachetka
	Title:	 	Chairman, President and CEO

  
 13 

 Attachment A 

The Purchased Assets, together with the Merck Covenant and rights granted to Horizon under the License Agreement, the Licensed Regulatory
Documentation, the APA Manufacturing Technology and any software or other ordinary course and immaterial Third Party licenses that are commercially available (excluding, for clarity, any license of any Patent Rights), constitute all of the
intellectual property, Regulatory Approvals and Regulatory Documentation necessary to (i) operate the Product Business, (ii) Manufacture or have Manufactured the Product in the Horizon Territory, and (iii) Manufacture, have
Manufactured, research and develop the Product in the AstraZeneca Territory solely for exportation and use of the Product in connection with the Exploitation of Product in the Horizon Territory, in each case ((i)—(iii)) in the same manner that
AstraZeneca and its Affiliates are operating the Product Business, Manufacturing or having Manufactured the Product in the Horizon Territory, and Manufacturing, having Manufactured, researching and developing the Product in the AstraZeneca Territory
for exportation and use of the Product in connection with the Exploitation of Product in the Horizon Territory, as applicable, as of the Execution Date and as of the Closing. In the event this Section 3.1.6(b) is breached because AstraZeneca
has failed to convey any Purchased Assets or to identify and either transfer to Horizon, or grant Horizon a license to or right of reference and use with respect to, as applicable, any intellectual property, Regulatory Approvals or Regulatory
Documentation necessary for the representation and warranty in this Section 3.1.6(b) to be true and correct in all respects, such breach shall be deemed cured as of the date AstraZeneca or any of its Affiliates specifically performs its
obligation under this Agreement or any Ancillary Agreement to convey title to all Purchased Assets to Horizon or to transfer to Horizon, or grant Horizon a license to or right of reference and use with respect to, as applicable, such intellectual
property, Regulatory Approvals or Regulatory Documentation at no additional cost or expense to Horizon; provided that such breach shall not be deemed cured with respect to any Losses incurred by any Horizon Indemnitee prior to such transfer or
grant. 

  
 14EX-10.49

 Exhibit 10.49 

***Text Omitted and Filed Separately with the Securities and Exchange Commission. 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

Master Manufacturing Services Agreement 

Master Manufacturing Services Agreement 

October 31, 2013 

 Master Manufacturing Services Agreement 

Table of Contents 
  

							
	 ARTICLE 1
	  	 	1	  
		
	 STRUCTURE OF AGREEMENT AND INTERPRETATION
	  	 	1	  
	 1.1
	 	MASTER AGREEMENT	  	 	1	  
	 1.2
	 	PRODUCT AGREEMENTS	  	 	1	  
	 1.3
	 	DEFINITIONS	  	 	2	  
	 1.4
	 	CURRENCY	  	 	6	  
	 1.5
	 	SECTIONS AND HEADINGS	  	 	6	  
	 1.6
	 	SINGULAR TERMS	  	 	7	  
	 1.7
	 	APPENDIX 1 AND EXHIBITS	  	 	7	  
		
	 ARTICLE 2
	  	 	8	  
		
	 PATHEON’S MANUFACTURING SERVICES
	  	 	8	  
	 2.1
	 	MANUFACTURING SERVICES	  	 	8	  
	 2.2
	 	ACTIVE MATERIAL YIELD	  	 	10	  
		
	 ARTICLE 3
	  	 	11	  
		
	 CLIENT’S OBLIGATIONS
	  	 	11	  
	 3.1
	 	PAYMENT	  	 	11	  
	 3.2
	 	ACTIVE MATERIALS AND QUALIFICATION OF ADDITIONAL SOURCES OF SUPPLY	  	 	11	  
		
	 ARTICLE 4
	  	 	12	  
		
	 CONVERSION FEES AND COMPONENT COSTS
	  	 	12	  
	 4.1
	 	FIRST YEAR PRICING	  	 	12	  
	 4.2
	 	PRICE ADJUSTMENTS – SUBSEQUENT YEARS’ PRICING	  	 	12	  
	 4.3
	 	PRICE ADJUSTMENTS – CURRENT YEAR PRICING	  	 	14	  
	 4.4
	 	ADJUSTMENTS DUE TO TECHNICAL CHANGES	  	 	14	  
	 4.5
	 	MULTI-COUNTRY PACKAGING REQUIREMENTS	  	 	15	  
		
	 ARTICLE 5
	  	 	15	  
		
	 ORDERS, SHIPMENT, INVOICING, PAYMENT
	  	 	15	  
	 5.1
	 	ORDERS AND FORECASTS	  	 	15	  
	 5.2
	 	RELIANCE BY PATHEON	  	 	16	  
	 5.3
	 	MINIMUM ORDERS	  	 	16	  
	 5.4
	 	SHIPMENTS	  	 	16	  
	 5.5
	 	LATE DELIVERY	  	 	17	  
	 5.6
	 	INVOICES AND PAYMENT	  	 	17	  

  
 - i - 

 Master Manufacturing Services Agreement 

 

							
		
	 ARTICLE 6
	  	 	17	  
		
	 PRODUCT CLAIMS AND RECALLS
	  	 	17	  
	 6.1
	 	PRODUCT CLAIMS	  	 	17	  
	 6.2
	 	PRODUCT RECALLS AND RETURNS	  	 	18	  
	 6.3
	 	PATHEON’S RESPONSIBILITY FOR DEFECTIVE AND RECALLED PRODUCTS	  	 	18	  
	 6.4
	 	DISPOSITION OF DEFECTIVE OR RECALLED PRODUCTS	  	 	19	  
	 6.5
	 	HEALTHCARE PROVIDER OR PATIENT QUESTIONS AND COMPLAINTS	  	 	19	  
	 6.6
	 	SOLE REMEDY	  	 	20	  
		
	 ARTICLE 7
	  	 	20	  
		
	 CO-OPERATION
	  	 	20	  
	 7.1
	 	QUARTERLY REVIEW	  	 	20	  
	 7.2
	 	GOVERNMENTAL AGENCIES	  	 	20	  
	 7.3
	 	RECORDS AND ACCOUNTING BY PATHEON	  	 	20	  
	 7.4
	 	INSPECTION	  	 	20	  
	 7.5
	 	ACCESS	  	 	21	  
	 7.6
	 	NOTIFICATION OF REGULATORY INSPECTIONS	  	 	21	  
	 7.7
	 	REPORTS	  	 	21	  
	 7.8
	 	REGULATORY FILINGS	  	 	21	  
		
	 ARTICLE 8
	  	 	22	  
		
	 TERM AND TERMINATION
	  	 	22	  
	 8.1
	 	INITIAL TERM	  	 	22	  
	 8.2
	 	TERMINATION FOR CAUSE	  	 	22	  
	 8.3
	 	PRODUCT DISCONTINUATION	  	 	23	  
	 8.4
	 	OBLIGATIONS ON TERMINATION	  	 	23	  
		
	 ARTICLE 9
	  	 	24	  
		
	 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	24	  
	 9.1
	 	AUTHORITY	  	 	24	  
	 9.2
	 	CLIENT WARRANTIES	  	 	24	  
	 9.3
	 	PATHEON WARRANTIES	  	 	25	  
	 9.4
	 	DEBARRED PERSONS	  	 	25	  
	 9.5
	 	PERMITS	  	 	26	  
	 9.6
	 	NO WARRANTY	  	 	26	  
		
	 ARTICLE 10
	  	 	26	  
		
	 REMEDIES AND INDEMNITIES
	  	 	26	  
	 10.1
	 	CONSEQUENTIAL DAMAGES	  	 	26	  
	 10.2
	 	LIMITATION OF LIABILITY	  	 	26	  

  
 - ii - 

 Master Manufacturing Services Agreement 

 

							
	 10.3
	 	PATHEON	  	 	26	  
	 10.4
	 	CLIENT	  	 	27	  
	 10.5
	 	REASONABLE ALLOCATION OF RISK	  	 	27	  
		
	 ARTICLE 11
	  	 	27	  
		
	 CONFIDENTIALITY
	  	 	27	  
	 11.1
	 	CONFIDENTIALITY	  	 	27	  
		
	 ARTICLE 12
	  	 	28	  
		
	 DISPUTE RESOLUTION
	  	 	28	  
	 12.1
	 	COMMERCIAL DISPUTES	  	 	28	  
	 12.2
	 	TECHNICAL DISPUTE RESOLUTION	  	 	28	  
		
	 ARTICLE 13
	  	 	28	  
		
	 MISCELLANEOUS
	  	 	28	  
	 13.1
	 	CORPORATE RESPONSIBILITY	  	 	28	  
	 13.2
	 	INVENTIONS	  	 	29	  
	 13.3
	 	INTELLECTUAL PROPERTY	  	 	29	  
	 13.4
	 	INSURANCE	  	 	29	  
	 13.5
	 	INDEPENDENT CONTRACTORS	  	 	30	  
	 13.6
	 	NO WAIVER	  	 	30	  
	 13.7
	 	ASSIGNMENT	  	 	30	  
	 13.8
	 	FORCE MAJEURE	  	 	30	  
	 13.9
	 	ADDITIONAL PRODUCT	  	 	31	  
	 13.10
	 	NOTICES	  	 	31	  
	 13.11
	 	SEVERABILITY	  	 	32	  
	 13.12
	 	ENTIRE AGREEMENT	  	 	32	  
	 13.13
	 	OTHER TERMS	  	 	32	  
	 13.14
	 	NO THIRD PARTY BENEFIT OR RIGHT	  	 	32	  
	 13.15
	 	EXECUTION IN COUNTERPARTS	  	 	32	  
	 13.16
	 	USE OF CLIENT NAME	  	 	32	  
	 13.17
	 	GOVERNING LAW	  	 	33	  

  
 - iii - 

 Master Manufacturing Services Agreement 

MASTER MANUFACTURING SERVICES AGREEMENT 

THIS MASTER MANUFACTURING SERVICES AGREEMENT (the “Agreement”) is made as of October 31, 2013 (the “Effective
Date”) 
 B E T W E E N: 

PATHEON PHARMACEUTICALS INC., 

a corporation existing under the laws of the State of Delaware 

(“Patheon”), 

- and - 

Horizon Pharma Inc., 

a corporation existing under the laws of the State of Delaware 

(“Client”). 

THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows: 

ARTICLE 1 
 STRUCTURE
OF AGREEMENT AND INTERPRETATION 
 1.1 Master Agreement.  

This Agreement establishes the general terms and conditions under which Patheon or any Affiliate of Patheon may perform Manufacturing Services
for Client or any Affiliate of Client, at the manufacturing site where the Affiliate of Patheon resides. This “master” form of agreement is intended to allow the parties, or any of their Affiliates, to contract for the manufacture of
multiple Products through Patheon’s global network of manufacturing sites through the issuance of site specific Product Agreements without having to re-negotiate the basic terms and conditions contained herein. 

1.2 Product Agreements. 

This Agreement is structured so that a Product Agreement may be entered into by the parties for the manufacture of a particular Product or
multiple Products at a Patheon manufacturing site. Each Product Agreement will be governed by the terms and conditions of this Agreement unless the parties to the Product Agreement expressly modify the terms and conditions of this Agreement in the
Product Agreement. Unless otherwise agreed by the parties, each Product Agreement will be in the general form and contain the information set forth in Appendix 1 hereto. 

  
 - 1 - 

 Master Manufacturing Services Agreement 

 

 1.3 Definitions. 

The following terms will, unless the context otherwise requires, have the respective meanings set out below and grammatical variations of these
terms will have corresponding meanings: 
 “Active Materials”, “Active Pharmaceutical Ingredients” or
“API” means the materials listed in a Product Agreement on Schedule D; 
 “Active Materials Credit Value”
means the value of the Active Materials for certain purposes of this Agreement, as set forth in a Product Agreement on Schedule D; 

“Actual Annual Yield” or “AAY” has the meaning specified in Section 2.2(a); 

“Affiliate” means: 
  

	 	(a)	a business entity which owns, directly or indirectly, a controlling interest in a party to this Agreement, by stock ownership or otherwise; or 

 

	 	(b)	a business entity which is controlled by a party to this Agreement, either directly or indirectly, by stock ownership or otherwise; or 

 

	 	(c)	a business entity, the controlling interest of which is directly or indirectly common to the majority ownership of a party to this Agreement; 

For this definition, “control” means the ownership of shares carrying at least a majority of the votes for the election of the
directors of a corporation; 
 “Annual Product Review Report” means the annual product review report prepared by Patheon as
described in Title 21 of the United States Code of Federal Regulations, Section 211.180(e); 
 “Annual Report” means
the annual report to the FDA prepared by Client regarding the Product as described in Title 21 of the United States Code of Federal Regulations, Section 314.81(b)(2); 

“Annual Volume” means the minimum volume of Product to be manufactured in any Year of this Agreement as set forth in Schedule
B; 
 “Applicable Laws” means (i) for Patheon, the Laws of the State of Ohio [or local jurisdiction for Patheon
Affiliate], being the jurisdiction where the Manufacturing Site is located; and (ii) for Client and the Products, the Laws of all jurisdictions where the Products are manufactured, distributed, and marketed as these are agreed and understood by
the parties in this Agreement; 
 “Authority” means any governmental or regulatory authority, department, body or agency or
any court, tribunal, bureau, commission or other similar body, whether federal, state, provincial, county or municipal; 
 “Bill Back
Items” means the expenses for all third party supplier fees for the purchase or use of columns, standards, tooling, non-standard pallets, PAPR or PPE suits (where applicable), RFID tags and supporting equipment, and other project-specific
items necessary for Patheon to perform the Manufacturing Services, and which are not included as Components; 
 “Breach
Notice” will have the meaning specified in Section 8.2(a); 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 

 “Business Day” means a day other than a Saturday, Sunday or a day that is a
statutory holiday in the United States; 
 “cGMPs” means, as applicable, current good manufacturing practices as described
in: 
  

	 	(a)	Division 2 of Part C of the Food and Drug Regulations (Canada); 

  

	 	(b)	Parts 210 and 211 of Title 21 of the United States’ Code of Federal Regulations; and 

  

	 	(c)	EC Directive 2003/94/EC, 

 together with the latest Health Canada, FDA and EMEA guidance
documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time; 
 “Client
Intellectual Property” means Intellectual Property generated or derived by Client before entering into this Agreement or during any Term of this Agreement, or by Patheon while performing any Manufacturing Services or otherwise generated or
derived by Patheon in its business which Intellectual Property is specific to, integral or dependent upon, Client’s Active Material or Product; 

“Client Property” will have the meaning specified in Section 8.4(e); 

“Client-Supplied Components” means those Components to be supplied by Client or that have been supplied by Client; 

“CMC” has the meaning specified in Section 7.8(c); 

“Components” means, collectively, all packaging components, raw materials, ingredients, and other materials (including labels,
product inserts and other labelling for the Products) required to manufacture the Products in accordance with the Specifications, other than the Active Materials; 

“Confidentiality Agreement” means the agreement about the non-disclosure of confidential information between Patheon and
Client dated September 27, 2013; 
 “Deficiencies” has the meaning specified in Section 7.8(d); 

“Deficiency Notice” has the meaning specified in Section 6.1(a); 

“Delivery Date” means the date scheduled for shipment of Product under a Firm Order as set forth in Section 5.1(d); 

“EMA” means the European Medicines Agency; 

[”Equipment” will have the meaning ascribed to it in {the Capital Equipment Agreement related to this MSA if any}] 

“FDA” means the United States Food and Drug Administration; 

“Firm Orders” has the meaning specified in Section 5.1(b); 

  
 - 3 - 

 Master Manufacturing Services Agreement 

 

 “Force Majeure” will have the meaning specified in Section 13.7; 

“Health Canada” means the section of the Canadian Government known as Health Canada and includes, among other departments, the
Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate; 
 “Initial Product Term” has the
meaning specified in Section 8.1; 
 “Initial Set Exchange Rate” means as of the Effective Date of a Product Agreement,
the initial exchange rate set forth in the Product Agreement to convert one unit of the billing currency into the Patheon Manufacturing Site local currency, calculated as the daily average interbank exchange rate for conversion of one unit of the
billing currency into the Patheon Manufacturing Site local currency during the 90 day period immediately preceding the Effective Date as published by OANDA.com “The Currency Site” under the heading “FxHistory: historical currency
exchange rates” at www.OANDA.com/convert/fxhistory; 
 “Initial Term” has the meaning specified in
Section 8.1; 
 “Intellectual Property” includes, without limitation, rights in patents, patent applications, formulae,
trademarks, trademark applications, trade-names, Inventions, copyrights, industrial designs, trade secrets, and know how; 

“Invention” means information about any innovation, improvement, development, discovery, computer program, device, trade
secret, method, know-how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which it is contained and whether or not patentable or copyrightable; 

“Inventory” means all inventories of Components and work-in-process produced or held by Patheon for the manufacture of the
Products but, for greater certainty, does not include the Active Materials; 
 “Late Delivery” has the meaning specified in
Section 5.5; 
 “Laws” means all laws, statutes, ordinances, regulations, rules, by-laws, judgments, decrees or orders
of any Authority; 
 “Manufacturing Services” means the manufacturing, quality control, quality assurance, stability
testing, bulk packaging and finished product packaging (if agreed between the parties in the relevant Product Agreement), and related services, as set forth in this Agreement, required to manufacture Product or Products using the Active Materials,
Components, and Bill Back Items; 
 “Manufacturing Site” means the facility owned and operated by Patheon where the
Manufacturing Services will be performed as identified in a Product Agreement; 
 “Materials” means all Components and Bill
Back Items required to manufacture the Products in accordance with the Specifications, other than the Active Materials; 
 “Maximum
Credit Value” means the maximum value of Active Materials that may be credited by Patheon under this Agreement, as set forth in a Product Agreement on Schedule D; 

  
 - 4 - 

 Master Manufacturing Services Agreement 

 

 “Minimum Order Quantity” means the minimum number of batches of a Product to
be produced during the same cycle of manufacturing as set forth in a Product Agreement on Schedule B; 
 “Patheon
Competitor” means an entity that generates greater than [...***...]% of its gross revenues from performing contract pharmaceutical commercial manufacturing services pursuant to arrangements with unrelated third party companies; 

“Patheon Intellectual Property” means Intellectual Property generated or derived by Patheon before performing any
Manufacturing Services, or generated or derived by Patheon in its business which Intellectual Property is not specific to, integral to, or dependent upon, Client’s Active Material or Product including, without limitation, Inventions and
Intellectual Property which may apply to manufacturing processes or the formulation or development of drug products, drug product dosage forms or drug delivery systems unrelated to the specific requirements of the Product(s); 

“Price” means the price measured in US Dollars to be charged by Patheon for performing the Manufacturing Services, and
includes the cost of Components (other than Client-Supplied Components), certain cost items as set forth in a Product Agreement on Schedule B, and annual stability testing costs as set forth in Schedule C; 

“Product(s)” means the product(s) listed in a Product Agreement on Schedule A; 

“Product Agreement” means the agreement between Patheon and Client issued under this Agreement in the form set forth in
Appendix 1 (including Schedules A to D) under which Patheon will perform Manufacturing Services at a particular Manufacturing Site; 

“Quality Agreement” means the agreement (the general form of which is set forth in Exhibit B) between the parties entering a
Product Agreement that sets out the quality assurance standards for the Manufacturing Services to be performed by Patheon for Client; 

“Recall” has the meaning specified in Section 6.2(a); 

“Regulatory Authority” means the FDA, EMA, and Health Canada and any other foreign regulatory agencies competent to grant
marketing approvals for pharmaceutical products including the Products in the Territory; 
 “RFID” means Radio Frequency
Identification Devices which (at present or in the future) may be affixed to Products or Materials to assist in inventory control, tracking, and identification; 

“Remediation Period” has the meaning specified in Section 8.2(a); 

“Set Exchange Rate” means the exchange rate to convert one unit of the billing currency into the Patheon Manufacturing Site
local currency for each Year, calculated as the average daily interbank exchange rate for conversion of one unit of the billing currency into the Patheon Manufacturing Site local currency during the full year period (October 1st [preceding year] to September 30th) .as published by OANDA.com “The Currency Site” under the heading “FxHistory: historical
currency exchange rates” at www.OANDA.com/convert/fxhistory; 
 “Shortfall” has the meaning specified in
Section 2.2(b); 

  
  

	***	Confidential Treatment Requested 

 - 5 - 

 Master Manufacturing Services Agreement 

 

 “Specifications” means the file, for each Product, which is given by Client
to Patheon in accordance with the procedures listed in a Product Agreement on Schedule A and which contains documents relating to each Product, including, without limitation: 
  

	 	(a)	specifications for Active Materials and Components; 

  

	 	(b)	manufacturing and testing specifications, directions, and processes; 

  

	 	(c)	storage requirements; 

  

	 	(d)	all environmental, health and safety information for each Product including material safety data sheets; and 

  

	 	(e)	the finished Product specifications, packaging specifications and shipping requirements for each Product; 

all as updated, amended and revised from time to time by Client in accordance with the terms of this Agreement; 

“Target Yield” has the meaning specified in Section 2.2(a); 

“Target Yield Determination Batches” has the meaning specified in Section 2.2(a); 

“Technical Dispute” has the meaning specified in Section 12.2; 

“Territory” means the geographic area described in a Product Agreement where Products manufactured by Patheon will be
distributed by Client; 
 “Third Party Rights” means the Intellectual Property of any third party; and 

“Year” means in the first year of this Agreement or in the first year of a Product Agreement, the period from the Effective
Date up to and including December 31 of the same calendar year, and thereafter will mean a calendar year. 
 1.4 Currency.  

Unless otherwise agreed in a Product Agreement, all monetary amounts expressed in this Agreement are in United States Dollars (USD). 

1.5 Sections and Headings.  

The division of this Agreement into Articles, Sections, Subsections, an Appendix, and Exhibits and the insertion of headings are for
convenience of reference only and will not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to a Section, Appendix or Exhibit refers to the specified Section, Appendix, or Exhibit to this
Agreement. In this Agreement, the terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressions refer to this Agreement and not to any particular part, Section,
Appendix or Exhibit of this Agreement. 

  
 - 6 - 

 Master Manufacturing Services Agreement 

 

 1.6 Singular Terms. 

Except as otherwise expressly stated or unless the context otherwise requires, all references to the singular will include the plural and vice
versa. 
 1.7 Appendix 1 and Exhibits. 

Appendix 1 and the following Exhibits are attached to, incorporated in, and form part of this Agreement: 

 

							
		 	 Appendix 1
	 	-	  	Form of Product Agreement (Including Schedules A to D)
				
		 	 Exhibit A
	 	-	  	Technical Dispute Resolution
		 	 Exhibit B
	 	-	  	Commercial Quality Agreement
		 	 Exhibit C
	 	-	  	Quarterly Active Materials Inventory Report
		 	 Exhibit D
	 	-	  	Report of Annual Active Materials Inventory Reconciliation and Calculation of Actual Annual Yield
		 	 Exhibit E
	 	-	  	Example of Price Adjustment Due to Currency Fluctuation

  
 - 7 - 

 Master Manufacturing Services Agreement 

 

 ARTICLE 2 

PATHEON’S MANUFACTURING SERVICES 

2.1 Manufacturing Services. 

Patheon will perform the Manufacturing Services for the Territory for the fees specified in a Product Agreement in Schedules B and C to
manufacture Products for Client. Schedule B to a Product Agreement sets forth a list of cost items that are included in the Price for Products; all cost items that are not included in this list are excluded from the Price and are subject to
additional fees to be paid by the Client. Patheon may amend the fees set out in Schedules B and C to a Product Agreement as set forth in Article 4. Patheon may change the Manufacturing Site for the Products only with the prior written consent of
Client, this consent not to be unreasonably withheld. Unless otherwise agreed in a Product Agreement, Patheon will manufacture at least [...***...]% of the Products offered for sale by Client in the Territory if Patheon remains in material
compliance with its obligations under this Agreement and the Product Agreement. In performing the Manufacturing Services, Patheon and Client agree that: 
  

	 	(a)	Conversion of Active Materials and Components. Patheon will convert Active Materials and Components into Products. 

  

	 	(b)	Quality Control and Quality Assurance. Patheon will perform the quality control and quality assurance testing specified in the Quality Agreement. Batch review and release to Client will be the responsibility of
Patheon’s quality assurance group. Patheon will perform its batch review and release responsibilities in accordance with Patheon’s standard operating procedures. Each time Patheon ships Products to Client, it will give Client a certificate
of analysis and certificate of compliance, including deviations as specified by the Quality Agreement, including a statement that the batch has been manufactured and tested in accordance with Specifications and cGMPs. Client will have sole
responsibility for the release of Products to the market. The form and style of batch documents, including, but not limited to, batch production records, lot packaging records, equipment set up control, operating parameters, and data printouts, raw
material data, and laboratory notebooks are the exclusive property of Patheon. Specific Product related information contained in those batch documents is Client property. 

 

	 	(c)	Components. Patheon will purchase and test all Components (with the exception of Client-Supplied Components) at Patheon’s expense and as required by the Specifications. 

 

	 	(d)	Stability Testing. Patheon will conduct stability testing on the Products in accordance with the protocols set out in the Specifications for the separate fees and during the time periods set out in
Schedule C to a Product Agreement. Patheon will not make any changes to these testing protocols without prior written approval from Client. If a confirmed stability test failure occurs, Patheon will notify Client within [...***...], after
which Patheon and Client will jointly determine the proceedings and methods to be undertaken to investigate the cause of the failure, including which party will bear the cost of the investigation. Patheon will not be liable for these costs unless it
has failed to perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws. Patheon will give Client all stability test data and results at Client’s request. 

 

	 	(e)	Packaging. Patheon will package the Products as set out in the Specifications. Client will be responsible for the cost of artwork development. Patheon will determine and imprint the batch numbers and expiration
dates for each Product shipped. The batch numbers 

  
  

	***	Confidential Treatment Requested 

 - 8 - 

 Master Manufacturing Services Agreement 

 

	 	
and expiration dates will be affixed on the Products and on the shipping carton of each Product as outlined in the Specifications and as required by cGMPs. Client may, in its sole discretion,
make changes to labels, product inserts, and other packaging for the Products. Those changes will be submitted by Client to all applicable governmental agencies and other third parties responsible for the approval of the Products. Client will be
responsible for the cost of labelling obsolescence when changes occur, as contemplated in Section 4.4. Patheon’s name will not appear on the label or anywhere else on the Products unless: (i) required by any Laws; or (ii) Patheon
consents in writing to the use of its name. 

  

	 	(f)	Active Materials and Client-Supplied Components. At least [...***...] days before the scheduled production date, Client will deliver the Active Materials and any Client-Supplied Components to the
Manufacturing Site [...***...] (Incoterms 2010), at no cost to Patheon, in sufficient quantity to enable Patheon to manufacture the desired quantities of Product and to ship Product on the Delivery Date. If the Active Materials and/or
Client-Supplied Components are not received [...***...] days before the scheduled production date, Patheon may delay the shipment of Product by the same number of days as the delay in receipt of the Active Materials and/or Client-Supplied
Components. But if Patheon is unable to manufacture Product to meet this new shipment date due to prior third party production commitments, Patheon may delay the shipment until a later date as agreed to by the parties. All shipments of Active
Material will be accompanied by certificate(s) of analysis from the Active Material manufacturer and the Client, confirming the identity and purity of the Active Materials and its compliance with the Active Material specifications. At a minimum,
Patheon will perform identity testing on each incoming lot of API and a full testing will be performed at least for one batch per year. Additional incoming tests to be performed on the API will be defined in the respective Product Agreement.

  

	 	(g)	Bill Back Items. Bill Back Items will be charged to Client at Patheon’s cost plus a [...***...]% handling fee for an item costing $[...***...] or less or, for an item costing in excess of
$[...***...], a handling fee of [...***...]%. 

  

	 	(h)	Validation Activities. Patheon may assist in the development and approval of the validation protocols for analytical methods and manufacturing procedures (including packaging procedures) for the Products. The
fees associated with Patheon’s assistance in providing validation development assistance are set out in Schedule C to a Product Agreement. 

  

	 	(i)	Product Rejection for Finished Product Specification Failure. Internal process specifications will be defined and agreed upon. If it is determined by a quality investigation that Patheon manufactured Product in
accordance with the agreed upon process specifications, the batch production record, and Patheon’s standard operating procedures for manufacturing, but a batch or portion of batch of Product does not meet a Finished Product Specification,
Client will pay Patheon the applicable fee per unit for the non-conforming Product. The API in the non-conforming Product will be included in the “Quantity Converted” for purposes of calculating the “Actual Annual Yield” under
Section 2.2(a). 

  
  

	***	Confidential Treatment Requested 

 - 9 - 

 Master Manufacturing Services Agreement 

 

 2.2 Active Material Yield.

 

	 	(a)	Reporting. Patheon will give Client a quarterly inventory report of the Active Materials held by Patheon using the inventory report form set out in Exhibit C, which will contain the following information for the
quarter: 

 Quantity Received: The total quantity of Active Materials that complies with the Specifications and is
received at the Manufacturing Site during the applicable period. 
 Quantity Dispensed: The total quantity of Active Materials
dispensed at the Manufacturing Site during the applicable period. The Quantity Dispensed is calculated by [...***...]. The Quantity Dispensed will only include Active Materials received and dispensed in commercial manufacturing of Products and, for
certainty, will not include any (i) Active Materials that must be retained by Patheon as samples, (ii) Active Materials contained in Product that must be retained as samples, (iii) Active Materials used in testing (if applicable), and
(iv) Active Materials received or dispensed in technical transfer activities or development activities during the applicable period, including without limitation, any regulatory, stability, validation or test batches manufactured during the
applicable period. 
 Quantity Converted: The total amount of Active Materials contained in the Products manufactured with the
Quantity Dispensed (including any additional Products produced in accordance with Section 6.3(a) or 6.3(b)), delivered by Patheon, and not rejected, recalled or returned in accordance with Section 6.1 or 6.2 because of Patheon’s
failure to perform the Manufacturing Services in accordance with Specifications, cGMPs, and Applicable Laws. 
 Within [...***...] days
after the end of each Year, Patheon will prepare an annual reconciliation of Active Materials on the reconciliation report form set forth in Exhibit D including the calculation of the “Actual Annual Yield” or “AAY”
for the Product at the Manufacturing Site during the Year. AAY is the percentage of the Quantity Dispensed that was converted to Products and is calculated as follows: 

Quantity Converted during the Year     x         100% 

Quantity Dispensed during the Year 

Unless otherwise agreed in a Product Agreement, after Patheon has produced a minimum of [...***...] successful commercial production
batches of Product and has produced commercial production batches for at least [...***...] months at the Manufacturing Site (collectively, the “Target Yield Determination Batches”), the parties will agree on the target yield
for the Product at the Manufacturing Site (each, a “Target Yield”); The Target Yield will be revised annually to reflect the actual manufacturing experience as agreed to by the parties. 

 

	 	(b)	Shortfall Calculation. If the Actual Annual Yield falls more than [...***...]% below the respective Target Yield in a Year, then the shortfall for the Year (the “Shortfall”) will be
calculated as follows: 

  
  

	***	Confidential Treatment Requested 

 - 10 - 

 Master Manufacturing Services Agreement 

 

 [...***...] 
  

	 	(c)	Credit for Shortfall. If there is a Shortfall for a Product in a Year, then Patheon will credit Client’s account for the amount of the Shortfall not later than [...***...] days after the end of the
Year. 

 Each credit under this Section 2.2(c) will be summarized on the reconciliation report form set forth in Exhibit
D. Upon expiration or termination of a Product Agreement, any remaining credit owing under this Section 2.2 will be paid to Client. The Annual Shortfall, if any, will be disclosed by Patheon on the reconciliation report form. 

 

	 	(d)	Maximum Credit. Patheon’s liability for Active Materials calculated in accordance with this Section 2.2 [for any Product] in a Year will not exceed, in the aggregate, the Maximum Credit Value set
forth in Schedule D to a Product Agreement. 

  

	 	(e)	No Material Breach. It will not be a material breach of this Agreement by Patheon under Section 8.2(a) if the Actual Annual Yield is less than the Target Yield. 

ARTICLE 3 

CLIENT’S OBLIGATIONS 
 3.1
Payment. 
 Client will pay Patheon for performing the Manufacturing Services according to the Prices specified in
Schedules B and C in a Product Agreement. These Prices may be subject to adjustment under other parts of this Agreement. Client will also pay Patheon for any Bill Back Items. 

3.2 Active Materials and Qualification of Additional Sources of Supply. 

Client will at its sole cost and expense, deliver the Active Materials to Patheon (in accordance with Section 2.1(f)) sufficient for
Patheon to manufacture the desired quantities of Product and to ship Product on the Delivery Date. If applicable, Patheon and the Client will reasonably cooperate to permit the import of the Active Materials to the Manufacturing Site. Client’s
obligation will include obtaining the proper release of the Active Materials from the applicable Customs Agency and Regulatory Authority. Client or Client’s designated broker will be the “Importer of Record” for Active Materials
imported to the Manufacturing Site. The Active Materials will be held by Patheon on behalf of Client as set forth in this Agreement. Title to the Active Materials will at all times remain the property of Client. Any Active Materials received by
Patheon will only be used by Patheon to perform the Manufacturing Services. If the Parties mutually determine a need to change the supplier of any Active Material or Component (other than a supplier that is specifically described in an applicable
Product Agreement), they will work together to develop a plan to qualify such additional supplier. 

  
  

	***	Confidential Treatment Requested 

 - 11 - 

 Master Manufacturing Services Agreement 

 

 ARTICLE 4 

CONVERSION FEES AND COMPONENT COSTS 

4.1 First Year Pricing. 

The tiered Price and annual stability Price for the Products for the first Year are listed in Schedules B and C in a Product Agreement and
are subject to the adjustments set forth in Sections 4.2 and 4.3. Upon Client’s request, Patheon will provide a breakdown of the manufacturing conversion costs, packaging conversion costs, and the Component costs for a Product. 

4.2 Price Adjustments – Subsequent Years’ Pricing. 

After the first Year of the Product Agreement, but in no case before [...***...], Patheon may adjust the Price effective January 1st of each Year as follows: 
  

	 	(a)	Manufacturing and Stability Testing Costs. For Products manufactured in the United States or Puerto Rico, Patheon may adjust the Price for inflation, based upon the preliminary number for any increase in the
Producer Price Index pcu325412325412 for Pharmaceutical Preparation Manufacturing (“PPI”) published by the United States Department of Labor, Bureau of Labor Statistics in August of the preceding Year compared to the final number
for the same month of the Year prior to that, unless the parties otherwise agree in writing. On or about November 1st of each Year, Patheon will give Client a statement setting forth the
calculation for the inflation adjustment to be applied in calculating the Price for the next Year. For Products manufactured outside the United States or Puerto Rico, Patheon may similarly adjust the Price for inflation using an inflation index to
be agreed by the parties in a Product Agreement. 

  

	 	(b)	Component Costs. If Patheon incurs an increase in Component costs during the Year, it may increase the Price for the next Year to pass through the additional Component costs. On or about November 1st of each
Year, Patheon will give Client information about the increase in Component costs which will be applied to the calculation of the Price for the next Year to reasonably demonstrate that the Price increase is justified. 

 

	 	(c)	Pricing Basis. Client acknowledges that the Price in any Year is quoted based upon the Minimum Order Quantity and the Annual Volume specified in Schedule B to a Product Agreement. The Price is subject to
change if [...***...]. 

  

	 	(d)	 Adjustments Due to Currency Fluctuations. If the parties agree in a Product Agreement to invoice in a currency other than the local currency
for the Manufacturing Site, Patheon will adjust the Price to reflect currency fluctuations. The adjustment will be calculated after all 

  
  

	***	Confidential Treatment Requested 

 - 12 - 

 Master Manufacturing Services Agreement 

 

	 	
other annual Price adjustments under this Section 4.2 have been made. The adjustment will proportionately reflect the increase or decrease, if any, in the Set Exchange Rate compared to the
Set Exchange Rate established for the prior Year or the Initial Set Exchange Rate, as the case may be. An example of the calculation of the price adjustment (for a Canadian Manufacturing Site invoiced in USD) is set forth in Exhibit E.

  

	 	(e)	Tier Pricing (if applicable). The pricing in Schedule B of a Product Agreement is set forth in Annual Volume tiers based upon the Client’s volume forecasts under Section 5.1. The Client will be
invoiced during the Year for the unit price set forth in the Annual Volume tier based on the [...***...] forecast provided in September of the previous Year. Within 

[...***...] days of the end of each Year or of the termination of the Agreement, Patheon will send Client a reconciliation of the
actual volume of Product ordered by the Client during the Year with the pricing tiers. If Client has overpaid during the Year, Patheon will issue a credit to the Client for the amount of the overpayment within [...***...] days of the end
of the Year or will issue payment to the Client for the overpayment within [...***...] days of the termination of the Agreement. If Client has underpaid during the Year, Patheon will issue an invoice to the Client under Section 5.6
for the amount of the underpayment within [...***...] days of the end of the Year or termination of the Agreement. If Client disagrees with the reconciliation, the parties will work in good faith to resolve the disagreement amicably. If
the parties are unable to resolve the disagreement within [...***...] days, the matter will be handled under Section 12.1. 
  

	 	(f)	Process Improvement Efforts. Patheon continually works to improve its processes to eliminate waste, improve cost efficiencies, deliver product as promised and adhere to strict quality standards. Patheon believes
in the continuous improvement of its performance, which led Patheon to create the Patheon Advantage program. Patheon Advantage incorporates Lean6Sigma to identify opportunities and implement changes to maximize the efficiency of Patheon’s
processes. If these improvement efforts result in quantifiable reductions in costs in providing the Services contemplated under this Agreement Patheon will promptly notify Client of the reductions, and the Price hereunder will be reduced by

 [...***...]% of the cost reduction from and after the date of the notice. 

For all Price adjustments under this Section 4.2, Patheon will deliver to Client on or about November 1st of each Year a revised Schedule B to the Product Agreement to be effective for Product delivered on or after the first day of the next Year. 

4.2.1 Price Adjustment due to Volume Changes from Yearly Forecast Volumes for Sterile Products. 

On the execution of a Product Agreement, Client will give to Patheon a forecast of the volume of Product required for the first
[...***...] Years of the Product Agreement (the “Yearly Forecast Volume” or “YFV”) that will become part of the Product Agreement. If at the end of the first Year the aggregate actual volume of Product ordered
by Client and invoiced by Patheon under Section 5.6 (“Actual Yearly Volume” or “AYV”) during the Year is less than the YFV as set out in the Product Agreement, then Client will pay Patheon for its non-absorbed
fixed manufacturing costs incurred during the Year in an amount to be determined as follows: 
 Amount due to
Patheon = [...***...] 

  
  

	***	Confidential Treatment Requested 

 - 13 - 

 Master Manufacturing Services Agreement 

 

 On or before June 10 of each Year, the parties will agree on the YFV for the next
[...***...] Years of the Product Agreement on a rolling forward basis. The forecast of the volume of Product for the second Year may not vary by more than [...***...]% from the original YFV for the second Year. Once agreed, the YFV
for the next Year will become binding on the parties and any amount due to Patheon will be determined as set forth above. 
 4.3 Price Adjustments
– Current Year Pricing. 
 During any Year, the Prices set out in Schedule B of a Product Agreement will be adjusted
as follows: 
 Extraordinary Increases in Component Costs. If, at any time, market conditions result in Patheon’s cost of
Components being materially greater than normal forecasted increases, then Patheon will be entitled to an adjustment to the Price for any affected Product to compensate it for the increased Component costs. Changes materially greater than normal
forecasted increases will have occurred if: (i) the cost of a Component increases by [...***...]% of the cost for that Component upon which the most recent fee quote was based; or (ii) the aggregate cost for all Components required
to manufacture a Product increases by 
 [...***...]% of the total Component costs for the Product upon which the most recent fee quote
was based. If Component costs have been previously adjusted to reflect an increase in the cost of one or more Components, the adjustments set out in (i) and (ii) above will operate based on the last cost adjustment for the Components. 

For a Price adjustment under this Section 4.3, Patheon will deliver to Client a revised Schedule B to the Product Agreement and budgetary
pricing information, adjusted Component costs or other documents reasonably sufficient to demonstrate that a Price adjustment is justified. Patheon will have no obligation to deliver any supporting documents that are subject to obligations of
confidentiality between Patheon and its suppliers. The revised Price will be effective for any Product delivered on or after the first day of the month following Client’s receipt of the revised Schedule B to the Product Agreement. 

4.4 Adjustments Due to Technical Changes. 

Amendments to the Specifications or the Quality Agreement requested by Client will only be implemented following a technical and cost review
that Patheon will perform at Client’s cost, and are subject to Client and Patheon reaching agreement on Price changes required because of the amendment. Amendments to the Specifications, the Quality Agreement, or the Manufacturing Site
requested by Patheon will only be implemented following the written approval of Client, the approval not to be unreasonably withheld. If Client accepts a proposed Price change, the proposed change in the Specifications will be implemented at
Client’s cost, and the Price change will become effective, only for those orders of Products that are manufactured under the revised Specifications. In addition, Client agrees to purchase, at Patheon’s cost (including all costs incurred by
Patheon for the purchase and handling of the Inventory), all Inventory used under the “old” Specifications and purchased or maintained by Patheon in order to fill Firm Orders or under Section 5.2, if the Inventory can no longer be
used under the revised Specifications. Open purchase orders for Components no longer required under any revised Specifications that were placed by Patheon with suppliers in order to fill Firm Orders or under Section 5.2 will be cancelled where
possible, and if the orders may not be cancelled without penalty, will be assigned to and satisfied by Client. If an amendment to the Specifications or the Quality Agreement becomes necessary as the result of changes to a compendia, the Parties will
discuss the necessary changes and Client will be solely responsible for the costs associated with these changes. 

  
  

	***	Confidential Treatment Requested 

 - 14 - 

 Master Manufacturing Services Agreement 

 

 4.5 Multi-Country Packaging Requirements.  

If Client decides to have Patheon perform Manufacturing Services for the Product for countries outside the Territory, then Client will inform
Patheon of the packaging requirements for each new country and Patheon will prepare a quotation for consideration by Client of any additional costs for Components (other than Client-Supplied Components) and the change over fees for the Product
destined for each new country. The agreed additional packaging requirements and related packaging costs and change over fees will be set out in a written amendment to this Agreement. 

ARTICLE 5 
 ORDERS,
SHIPMENT, INVOICING, PAYMENT 
 5.1 Orders and Forecasts.  

 

	 	(a)	Rolling [...***...] Month Forecast. When each Product Agreement is executed, Client will give Patheon a non-binding
 [...***...] month
forecast of the volume of Product that Client expects to order in the first [...***...] months of commercial manufacture of the Product. This forecast will then be updated by Client on or before the [...***...] day of each month on a
rolling forward basis. Client will update the forecast forthwith if it determines that the volumes estimated in the most recent forecast have changed by more than [...***...]%. The most recent [...***...] month forecast will prevail.

  

	 	(b)	Firm Orders. On a rolling basis during the term of the Product Agreement, Client will issue an updated [...***...] month forecast on or before the [...***...] day of each month. This forecast will
start on the first day of the next month. The first [...***...] months of this updated forecast will be considered binding firm orders. Concurrent with the [...***...] month forecast, Client will issue a new firm written order in the
form of a purchase order or otherwise (“Firm Order”) by Client to purchase and, when accepted by Patheon, for Patheon to manufacture and deliver the agreed quantity of the Products. The Delivery Date will not be less than
[...***...] days following the date that the Firm Order is submitted. Firm Orders submitted to Patheon will specify Client’s purchase order number, quantities by Product type, monthly delivery schedule, and any other elements necessary to
ensure the timely manufacture and shipment of the Products. The quantities of Products ordered in those written orders will be firm and binding on Client and may not be reduced by Client. 

 

	 	(c)	[...***...] Year Forecast. On or before the [...***...] of each Year, Client will give Patheon a written non-binding
 [...***...]-year forecast, broken down by quarters for the
[...***...] and [...***...] years of the forecast, of the volume of each Product Client then anticipates will be required to be manufactured and delivered to Client during the [...***...]-year period. 

 

	 	(d)	Acceptance of Firm Order. Patheon will accept Firm Orders by sending an acknowledgement to Client within [...***...] Business Days of its receipt of the Firm Order. The acknowledgement will include, subject
to confirmation from the Client, the Delivery Date for the Product ordered. The Delivery Date may be amended by agreement of the parties or as set forth in Section 2.1(f). 

  
  

	***	Confidential Treatment Requested 

 - 15 - 

 Master Manufacturing Services Agreement 

 

 5.2 Reliance by Patheon. 

(a) Client understands and acknowledges that Patheon will rely on the Firm Orders and rolling forecasts submitted under Sections 5.1(a), and
(b) in ordering the Components (other than Client-Supplied Components) required to meet the Firm Orders. In addition, Client understands that to ensure an orderly supply of the Components, Patheon may want to purchase the Components in
sufficient volumes to meet the production requirements for Products during part or all of the forecasted periods referred to in Section 5.1(a) or to meet the production requirements of any longer period agreed to by Patheon and Client.
Accordingly, Client authorizes Patheon to purchase Components to satisfy the Manufacturing Services requirements for Products for the first [...***...] months contemplated in the most
recent forecast given by Client under Section 5.1(a). Patheon may make other purchases of Components to meet Manufacturing Services requirements for longer periods if agreed to in writing by the parties. The Client will give Patheon written
authorization to order Components for any launch quantities of Product requested by Client which will be considered a Firm Order when accepted by Patheon. If Components ordered by Patheon under Firm Orders or this Section 5.2 are not included
in finished Products manufactured for Client within [...***...] months after the forecasted month for which the purchases have been made (or for a longer period as the parties may agree) or if the Components have expired during the period,
then Client will pay to Patheon its costs therefor (including all costs incurred by Patheon for the purchase and handling of the Components). But if these Components are used in Products subsequently manufactured for Client or in third party
products manufactured by Patheon, Client will receive credit for any costs of those Components previously paid to Patheon by Client. 
 (b)
If Client fails to take possession or arrange for the destruction of Components within [...***...] months of purchase or, in the case of finished Product, within [...***...] of manufacture, Client will pay Patheon $[...***...] per
pallet, per month thereafter for storing the Components or finished Product. Storage fees for Components or Product which contain controlled substances or require refrigeration will be charged at $[...***...] per pallet per month. Storage fees
are subject to a one pallet minimum charge per month. Patheon may ship finished Product held by it longer than [...***...] to the Client at Client’s expense on [...***...] days written notice to the Client. 

5.3 Minimum Orders. 
 Client
may only order Manufacturing Services for batches of Products in multiples of the Minimum Order Quantities as set out in Schedule B to a Product Agreement. 

5.4 Shipments. 
 Shipments of
Products will be made [...***...] (Incoterms 2010) Patheon’s shipping point unless otherwise agreed in a Product Agreement. Risk of loss or of damage to Products will remain with Patheon until Patheon loads the Products onto the
carrier’s vehicle for shipment at which time risk of loss or damage will transfer to Client. Patheon will, in accordance with Client’s instructions and as agent for Client, (i) arrange for shipping to be paid by Client and
(ii) obtain any export license or other official authorization necessary to export the Products. Client will arrange for insurance and will select the freight carrier used by Patheon to ship Products and may monitor Patheon’s shipping and
freight practices as they pertain to this Agreement. Products will be transported in accordance with the Specifications. 

  
  

	***	Confidential Treatment Requested 

 - 16 - 

 Master Manufacturing Services Agreement 

 

 5.5 Late Delivery  

If Patheon is unable to deliver the quantity of Product ordered under a Firm Order within
[...***...] of the Delivery Date due to an act or omission by Patheon (a “Late Delivery”), Client will receive a credit from Patheon for the Late Delivery that will be
applied against the purchase price under the next Firm Order. The credit will be [...***...]% of the Price of the quantities of Product not delivered by Patheon under the Firm Order within [...***...] of the Delivery Date
[...***...]. An additional credit of [...***...]% of the Price of the quantities of Product not delivered by Patheon under a Firm Order will accrue for each additional [...***...] of the Late Delivery up to a maximum aggregate
credit of [...***...]%. A Late Delivery will not be a material breach of this Agreement by Patheon for the purposes of Section 8.2(a). For clarity, a Late Delivery will not include any delay in shipment of Product caused by events outside
of Patheon’s reasonable control, such as a Force Majeure Event, a delay in delivery of API or Materials, a delay in Product release approval from Client, inaccurate Client forecasts, receipt of non-conforming API or Client-Supplied Components,
or any market driven delays in deliveries from approved vendors. 
 5.6 Invoices and Payment. 

Invoices will be sent by fax or email to the fax number or email address given by Client to Patheon in writing. Invoices will be sent when the
Product is manufactured and released by Patheon to the Client. Patheon will also submit to Client, with each shipment of Products, a duplicate copy of the invoice covering the shipment. Patheon will also give Client an invoice covering any Inventory
or Components which are to be purchased by Client under Section 5.2 of this Agreement. Each invoice will, to the extent applicable, identify Client’s Manufacturing Services purchase order number, Product numbers, names and quantities, unit
price, freight charges, and the total amount to be paid by Client. Client will pay all invoices within [...***...] days of the date thereof. If any portion of an invoice is disputed, the Client will pay Patheon for the undisputed amount and
the parties will use good faith efforts to reconcile the disputed amount as soon as practicable. Beginning [...***...] days after the date of the invoice, interest on undisputed past due accounts will accrue at [...***...]% per month
which is equal to an annual rate of [...***...]%. The Late Delivery credits set forth in Section 5.5 are only available to Client if all outstanding undisputed invoices have been paid in full or are within [...***...] days
outstanding from the invoice date when the Late Delivery arose. 
 ARTICLE 6 

PRODUCT CLAIMS AND RECALLS 
 6.1
Product Claims. 
 (a) Product Claims. Client has the right to reject any portion of any shipment of Products that
deviates from the Specifications, cGMPs, or Applicable Laws without invalidating any remainder of the shipment. Client will inspect the Products manufactured by Patheon upon receipt and will give Patheon written notice (a “Deficiency
Notice”) of all claims for Products that deviate from the Specifications, cGMPs, or Applicable Laws within [...***...] days after Client’s receipt thereof (or, in the case of any defects not reasonably susceptible to discovery
upon receipt of the Product, within [...***...] days after discovery by Client, but not after the expiration date of the Product). Should Client fail to give Patheon the Deficiency Notice within the applicable [...***...] day period,
then the delivery will be deemed to have been accepted by Client on the [...***...] day after delivery or discovery, as applicable. Except as set out in Section 6.3, Patheon will have no liability for any deviations for which it has not
received notice within the applicable [...***...] day period. 

  
  

	***	Confidential Treatment Requested 

 - 17 - 

 Master Manufacturing Services Agreement 

 

 (b) Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon will
have [...***...] days to advise Client by notice in writing that it disagrees with the contents of the Deficiency Notice. If Client and Patheon fail to agree within [...***...] days after Patheon’s notice to Client as to whether any
Products identified in the Deficiency Notice deviate from the Specifications, cGMPs, or Applicable Laws, then the parties will mutually select an independent laboratory to evaluate if the Products deviate from the Specifications, cGMPs, or
Applicable Laws. This evaluation will be binding on the parties. If the evaluation certifies that any Products deviate from the Specifications, cGMPs, or Applicable Laws, Client may reject those Products in the manner contemplated in this
Section 6.1 and Patheon will be responsible for the cost of the evaluation. If the evaluation does not so certify for any of the Products, then Client will be deemed to have accepted delivery of the Products on the [...***...] day after
delivery (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, on the [...***...] day after discovery thereof by Client, but not after the expiration date of the Product) and Client will be
responsible for the cost of the evaluation. 
 (c) Shortages. Claims for shortages in the amount of Products shipped by Patheon will
be dealt with by reasonable agreement of the parties. 
 6.2 Product Recalls and Returns. 

(a) Records and Notice. Patheon and Client will each maintain records necessary to permit a Recall of any Products delivered to Client
or customers of Client. Each party will promptly notify the other by telephone (to be confirmed in writing) of any information which might affect the marketability, safety or effectiveness of the Products or which might result in the Recall or
seizure of the Products. Upon receiving this notice or upon this discovery, each party will stop making any further shipments of any Products in its possession or control until a decision has been made whether a Recall or some other corrective
action is necessary. The decision to initiate a Recall or to take some other corrective action, if any, will be made and implemented by Client. “Recall” will mean any action (i) by Client to recover title to or possession of
quantities of the Products sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Products from the market); or (ii) by any regulatory authorities to detain or destroy any of the Products. Recall will also
include any action by either party to refrain from selling or shipping quantities of the Products to third parties which would have been subject to a Recall if sold or shipped. 

(b) Recalls. If (i) any governmental or regulatory authority issues a directive, order or, following the issuance of a safety
warning or alert about a Product, a written request that any Product be Recalled, (ii) a court of competent jurisdiction orders a Recall, or (iii) Client determines that any Product should be Recalled or that a “Dear Doctor”
letter is required relating the restrictions on the use of any Product, Patheon will co-operate as reasonably required by Client, having regard to all applicable laws and regulations. 

(c) Product Returns. Client will have the responsibility for handling customer returns of the Products. Patheon will give Client any
assistance that Client may reasonably require to handle the returns. 
 6.3 Patheon’s Responsibility for Defective and Recalled Products.

 (a) Defective Product. If Client rejects Products under Section 6.1 and the deviation is determined to have arisen from
Patheon’s failure to provide the Manufacturing Services in accordance with the Specifications, cGMPs, or Applicable Laws, Patheon will credit Client’s account for Patheon’s invoice price for the defective Products. If Client
previously paid for the defective Products, Patheon will promptly, at Client’s election, either: (i) refund the invoice price for the defective Products; (ii) offset the 

  
  

	***	Confidential Treatment Requested 

 - 18 - 

 Master Manufacturing Services Agreement 

 

 
amount paid against other amounts due to Patheon hereunder; or (iii) replace the Products with conforming Products without Client being liable for payment therefor under Section 3.1,
contingent upon the receipt from Client of all Active Materials and Client-Supplied Components required for the manufacture of the replacement Products. For greater certainty, Patheon’s responsibility for any loss of Active Materials in
defective Product will be captured and calculated in the Active Materials Yield under Section 2.2. 
 (b) Recalled Product. If a
Recall or return results from, or arises out of, a failure by Patheon to perform the Manufacturing Services in accordance with the Specifications, cGMPs, or Applicable Laws, Patheon will be responsible for the documented out-of-pocket expenses of
the Recall or return and will use its commercially reasonable efforts to replace the Recalled or returned Products with new Products, contingent upon the receipt from Client of all Active Materials and Client-Supplied Components required for the
manufacture of the replacement Products. For greater certainty, Patheon’s responsibility for any loss of Active Materials in Recalled Product will be captured and calculated in the Active Materials Yield under Section 2.2. If Patheon is
unable to replace the Recalled or returned Products (except where this inability results from a failure to receive the required Active Materials and Client-Supplied Components), then Client may request Patheon to reimburse Client for the price that
Client paid to Patheon for Manufacturing Services for the affected Products. In all other circumstances, Recalls, returns, or other corrective actions will be made at Client’s cost and expense. 

(c) Except as set forth in Sections 6.3(a) and (b) above, Patheon will not be liable to Client nor have any responsibility to Client for
any deficiencies in, or other liabilities associated with, any Product manufactured by it, (collectively, “Product Claims”). For greater certainty, Patheon will have no obligation for any Product Claims to the extent the Product
Claim (i) is caused by deficiencies in the Specifications, the safety, efficacy, or marketability of the Products or any distribution thereof, (ii) results from a defect in a Component that is not reasonably discoverable by Patheon using
the test methods set forth in the Specifications, (iii) results from a defect in the Active Materials or Client-Supplied Components that is not reasonably discoverable by Patheon using the test methods set forth in the Specifications,
(iv) is caused by actions of third parties occurring after the Product is shipped by Patheon under Section 5.4, (v) is due to packaging design or labelling defects or omissions for which Patheon has no responsibility, (vi) is due
to any unascertainable reason despite Patheon having performed the Manufacturing Services in accordance with the Specifications, cGMP’s, and Applicable Laws, or (vii) is due to any other breach by Client of its obligations under this
Agreement. 
 6.4 Disposition of Defective or Recalled Products. 

Client will not dispose of any damaged, defective, returned, or Recalled Products for which it intends to assert a claim against Patheon
without Patheon’s prior written authorization to do so. Alternatively, Patheon may instruct Client to return the Products to Patheon. Patheon will bear the cost of disposition for any damaged, defective, returned or Recalled Products for which
it bears responsibility under Section 6.3. In all other circumstances, Client will bear the cost of disposition, including all applicable fees for Manufacturing Services, for any damaged, defective, returned, or Recalled Products. 

6.5 Healthcare Provider or Patient Questions and Complaints. 

Client will have the sole responsibility for responding to questions and complaints from its customers. Questions or complaints received by
Patheon from Client’s customers, healthcare providers or patients will be promptly referred to Client. Patheon will co-operate as reasonably required to allow Client to determine the cause of and resolve any questions and complaints. This
assistance will include follow-up investigations, including testing. In addition, Patheon will give Client all agreed upon information that will enable Client to respond properly to questions or complaints about the Products as

  
 - 19 - 

 Master Manufacturing Services Agreement 

 

 
set forth in the Quality Agreement. Unless it is determined that the cause of the complaint resulted from a failure by Patheon to perform the Manufacturing Services in accordance with the
Specifications, cGMPs, and Applicable Laws, all costs incurred under this Section 6.5 will be borne by Client. 
 6.6 Sole Remedy.

 Except for the indemnity set forth in Section 10.3 and subject to the limitations set forth in Sections 10.1 and 10.2, the
remedies described in this Article 6 will be Client’s sole remedy for any failure by Patheon to provide the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws. 

ARTICLE 7 

CO-OPERATION 
 7.1 Quarterly
Review. 
 Each party will forthwith upon execution of this Agreement appoint one of its employees to be a relationship
manager responsible for liaison between the parties. The relationship managers will meet not less than quarterly to review the current status of the business relationship and manage any issues that have arisen. 

7.2 Governmental Agencies. 

Subject to Section 7.8, each party may communicate with any governmental agency, including but not limited to governmental agencies
responsible for granting regulatory approval for the Products, regarding the Products if, in the opinion of that party’s counsel, the communication is necessary to comply with the terms of this Agreement or the requirements of any law,
governmental order or regulation. Unless, in the reasonable opinion of its counsel, there is a legal prohibition against doing so, a party will permit the other party to accompany and take part in any communications with the agency, and to receive
copies of all communications from the agency. 
 7.3 Records and Accounting by Patheon. 

Patheon will keep records of the manufacture, testing, and shipping of the Products, and retain samples of the Products as are necessary to
comply with manufacturing regulatory requirements applicable to Patheon, as well as to assist with resolving Product complaints and other similar investigations. Copies of the records and samples will be retained for [...***...] following the date
of Product expiry, or longer if required by law, at which time Client will be contacted concerning the delivery and destruction of the documents and/or samples of Products. Client is responsible for retaining samples of the Products necessary to
comply with the legal/regulatory requirements applicable to Client. 
 7.4 Inspection. 

Client may inspect Patheon reports and records relating to this Agreement during normal business hours and with reasonable advance notice, but
a Patheon representative must be present during the inspection. 

  
  

	***	Confidential Treatment Requested 

 - 20 - 

 Master Manufacturing Services Agreement 

 

 7.5 Access. 

Patheon will give Client reasonable access at agreed times to the areas of the Manufacturing Site in which the Products are manufactured,
stored, handled, or shipped to permit Client to verify that the Manufacturing Services are being performed in accordance with the Specifications, cGMPs, and Applicable Laws. But, with the exception of “for-cause” audits, Client will be
limited each Year to one cGMP-type audit, lasting no more than [...***...] days, and involving no more than [...***...] auditors. Client may request additional cGMP-type audits, additional audit days, or the participation of additional
auditors subject to payment to Patheon of a fee of $[...***...] for each additional audit day and $[...***...] per audit day for each additional auditor. The right of access set forth in this Section 7.5 will not include a right to
access or inspect Patheon’s financial records. In addition to any other rights to audit, otherwise described in this Agreement, Client will have the right to have up to [...***...] representatives present for [...***...] days during
the manufacturing campaigns of any Product during normal business hours and upon reasonable advance notice to Patheon. If Client’s representatives are present for more than [...***...] days during the manufacturing campaigns of any
Products, Client will pay Patheon a fee of $[...***...] per day for each additional day. 
 7.6 Notification of Regulatory
Inspections. 
 Patheon will notify Client within [...***...] of any inspections by any governmental agency specifically
involving the Products. Patheon will also notify Client of receipt of any form 483’s or warning letters or any other significant regulatory action which Patheon’s quality assurance group determines could impact the regulatory status of the
Products. 
 7.7 Reports. 

Patheon will supply on an annual basis all Product data in its control, including release test results, complaint test results, and all
investigations (in manufacturing, testing, and storage), that Client reasonably requires in order to complete any filing under any applicable regulatory regime, including any Annual Report that Client is required to file with the FDA. At the
Client’s request, Patheon will provide a copy of the Annual Product Review Report to the Client at no additional cost. Any additional report requested by Client beyond the scope of cGMPs and customary FDA requirements will be subject to an
additional fee to be agreed upon between Patheon and the Client. 
 7.8 Regulatory Filings. 

(a) Regulatory Authority. Client will have the sole responsibility for filing all documents with all Regulatory Authorities and taking
any other actions that may be required for the receipt and/or maintenance of Regulatory Authority approval for the commercial manufacture of the Products. Patheon will assist Client, to the extent consistent with Patheon’s obligations under
this Agreement, to obtain Regulatory Authority approval for the commercial manufacture of all Products as quickly as reasonably possible. 

(b) Verification of Data. Prior to filing any documents with any Regulatory Authority that incorporate data generated by Patheon, Client
will give Patheon a copy of the documents incorporating this data to give Patheon the opportunity to verify the accuracy and regulatory validity of those documents as they relate to Patheon generated data. Patheon requires [...***...] days to
perform this review but the parties may agree to a shorter time for the review as needed. 

  
  

	***	Confidential Treatment Requested 

 - 21 - 

 Master Manufacturing Services Agreement 

 

 (c) Verification of CMC. Prior to filing with any Regulatory Authority any
documentation which is or is equivalent to the FDA’s Chemistry and Manufacturing Controls (all such documentation herein referred to as “CMC”) related to any Marketing Authorization, such as a New Drug Application or
Abbreviated New Drug Application, Client will give Patheon a copy of the CMC as well as all supporting documents which have been relied upon to prepare the CMC. This disclosure will permit Patheon to verify that the CMC accurately describes the work
that Patheon has performed and the manufacturing processes that Patheon will perform under this Agreement. Patheon requires [...***...] days to perform this review but the parties may agree
to a shorter time for the review as needed. Client will give Patheon copies of all FDA filings which contain CMC information regarding the Product within [...***...] days of the approval submission. 

(d) Deficiencies. If, in Patheon’s sole discretion, acting reasonably, Patheon determines that any of the information given by
Client under clauses (b) and (c) above is inaccurate or deficient in any manner whatsoever (the “Deficiencies”), Patheon will notify Client in writing of the Deficiencies. The parties will work together to have the
Deficiencies resolved prior to any pre-approval inspection. 
 (e) Client Responsibility. For clarity, the parties agree that in
reviewing the documents referred to in clause (b) above, Patheon’s role will be limited to verifying the accuracy of the description of the work undertaken or to be undertaken by Patheon. Subject to the foregoing, Patheon will not assume
any responsibility for the accuracy of any application for receipt of an approval by a Regulatory Authority. The Client is solely responsible for the preparation and filing of the application for approval by the Regulatory Authority and any relevant
costs will be borne by the Client. 
 (f) Inspection by Regulatory Authorities. If Client does not give Patheon the documents
requested under clause (b) above within the time specified and if Patheon reasonably believes that Patheon’s standing with a Regulatory Authority may be jeopardized, Patheon may, in its sole discretion, delay or postpone any inspection by
the Regulatory Authority until Patheon has reviewed the requested documents and is satisfied with their contents. 
 ARTICLE 8 

TERM AND TERMINATION 
 8.1
Initial Term. 
 This Agreement will become effective as of the Effective Date and will continue until December 31,
2019 (the “Initial Term”), unless terminated earlier by one of the parties in accordance herewith. This Agreement will automatically renew after the Initial Term for successive terms of [...***...] Years each if there is a
Product Agreement in effect, unless either party gives written notice to the other party of its intention to terminate this Agreement at least [...***...] months prior to the end of the then current term. In any event, the legal terms and
conditions of this Agreement will continue to govern any Product Agreement in effect as provided in Section 1.2. Each Product Agreement will have an initial term of [...***...] Years from the start of commercial manufacture at the
Manufacturing Site for the Product unless the parties agree to a different number of Years in the applicable Product Agreement (each, an “Initial Product Term”). Product Agreements will automatically renew after the Initial Product
Term for successive terms of [...***...] Years each unless either party gives written notice to the other party of its intention to terminate the Product Agreement at least [...***...] months prior to the end of the then current term.

 8.2 Termination for Cause. 

(a) Either party at its sole option may terminate this Agreement or a Product Agreement upon written notice where the other party has failed to
remedy a material breach of any of its representations, 

  
  

	***	Confidential Treatment Requested 

 - 22 - 

 Master Manufacturing Services Agreement 

 

 
warranties, or other obligations under this Agreement or the Product Agreement within [...***...] days following receipt of a written
notice (the “Remediation Period”) of the breach that expressly states that it is a notice under this Section 8.2(a) (a “Breach Notice”). The aggrieved party’s right to terminate this Agreement or a Product
Agreement under this Section 8.2(a) may only be exercised for a period of [...***...] days following the expiry of the Remediation Period (where the breach has not been remedied) and if the termination right is not exercised during this
period then the aggrieved party will be deemed to have waived the breach of the representation, warranty, or obligation described in the Breach Notice. 

(b) Either party at its sole option may immediately terminate this Agreement or a Product Agreement upon written notice, but without prior
advance notice, to the other party if: (i) the other party is declared insolvent or bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by the other party;
or (iii) this Agreement or a Product Agreement is assigned by the other party for the benefit of creditors. 
 (c) Client may terminate
a Product Agreement upon [...***...] days’ prior written notice if any Authority takes any action, or raises any objection, that prevents Client from importing, exporting, purchasing, or selling the Product. But if this occurs, Client
must still fulfill all of its obligations under Section 8.4 below and under any Capital Equipment Agreement regarding the Product. 

(d) Patheon may terminate this Agreement or a Product Agreement upon [...***...] months’ prior written notice if Client assigns
under Section 13.6 any of its rights under this Agreement or a Product Agreement to an assignee that, in the reasonable opinion of Patheon, is: (i) not a credit worthy substitute for Client or (ii) a Patheon Competitor. 

8.3 Product Discontinuation. 

Client will give at least [...***...] months’ advance notice if it intends to no longer order Manufacturing Services for a Product
due to this Product’s discontinuance in the market. 
 8.4 Obligations on Termination. 

If a Product Agreement is completed, expires, or is terminated in whole or in part for any reason, then: 

 

	 	(a)	Client will take delivery of and pay for all undelivered Products that are manufactured and/or packaged under a Firm Order, at the price in effect at the time the Firm Order was placed, subject to Client’s right to
reject any such Product as described in Article 6 of this Agreement; 

  

	 	(b)	Client will purchase, at Patheon’s cost (including all costs incurred by Patheon for the purchase and handling of the Inventory), the Inventory applicable to the Products which was purchased, produced or maintained
by Patheon in contemplation of filling Firm Orders or in accordance with Section 5.2, but not including Components which Patheon can use in its other Manufacturing operations and not including any Inventory that has been stored or otherwise
maintained in an environment that a Regulatory Authority has determined, or would reasonably determine, is not cGMP compliant; 

  

	 	(c)	Client will satisfy the purchase price payable under Patheon’s orders with suppliers of Components, if the orders were made by Patheon in reliance on Firm Orders or in accordance with Section 5.2;

  
  

	***	Confidential Treatment Requested 

 - 23 - 

 Master Manufacturing Services Agreement 

 

	 	(d)	Client acknowledges that no Patheon Competitor will be permitted access to the Manufacturing Site; and 

  

	 	(e)	Client will make commercially reasonable efforts, at its own expense, to remove from Patheon site(s), within [...***...] days, all unused Active Material and Client-Supplied Components, all applicable Inventory and
Materials (whether current or obsolete), supplies, undelivered Product, chattels, [E]equipment or other moveable property owned by Client, related to the Agreement and located at a Patheon site or that is otherwise under Patheon’s care
and control (“Client Property”). If Client fails to remove the Client Property within [...***...] days following the completion, termination, or expiration of the Product Agreement, Client will pay Patheon $[...***...]
per pallet, per month, one pallet minimum (except that Client will pay $[...***...] per pallet, per month, one pallet minimum, for any of the Client Property that contains controlled substances, requires refrigeration or other special storage
requirements) thereafter for storing the Client Property and will assume any third party storage charges invoiced to Patheon regarding the Client Property. Patheon will invoice Client for the storage charges as set forth in Section 5.6 of this
Agreement. 

  

	 	(f)	The parties will reasonably cooperate to support the transfer of the manufacture of the Products to a third party manufacturer. 

Any termination or expiration of this Agreement or a Product Agreement will not affect any outstanding obligations or payments due prior to the termination or
expiration, nor will it prejudice any other remedies that the parties may have under this Agreement or a Product Agreement or any related Capital Equipment Agreement. For greater certainty, termination of this Agreement or of a Product Agreement for
any reason will not affect the obligations and responsibilities of the parties under Articles 6, 10 and 11 and Sections 5.4, 5.6, 8.4, 13.1, 13.2, 13.3, and 13.16, all of which survive any termination. 

ARTICLE 9 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

9.1 Authority. 
 Each party
covenants, represents, and warrants that it has the full right and authority to enter into this Agreement and that it is not aware of any impediment that would inhibit its ability to perform its obligations hereunder. 

9.2 Client Warranties. 

Client covenants, represents, and warrants that: 
  

	 	(a)	Non-Infringement. 

  

	 	(i)	the Specifications for each of the Products are its or its Affiliate’s property and that Client may lawfully disclose the Specifications to Patheon; 

 

	 	(ii)	any Client Intellectual Property, used by Patheon in performing the Manufacturing Services according to the Specifications (A) is Client’s or its Affiliate’s unencumbered property, (B) may be
lawfully used as directed by Client, and (C) does not infringe and will not infringe any Third Party Rights; 

  
  

	***	Confidential Treatment Requested 

 - 24 - 

 Master Manufacturing Services Agreement 

 

	 	(iii)	the performance of the Manufacturing Services by Patheon for any Product under this Agreement or any Product Agreement or the use or other disposition of any Product by Patheon as may be required to perform its
obligations under this Agreement or under any Product Agreement does not and will not infringe any Third Party Rights; 

  

	 	(iv)	there are no actions or other legal proceedings, concerning the infringement of Third Party Rights related to any of the Specifications, or any of the Active Materials and the Components, or the sale, use, or other
disposition of any Product made in accordance with the Specifications; 

  

	 	(b)	Quality and Compliance. 

  

	 	(i)	the Specifications for all Products conform to all applicable cGMPs and Applicable Laws; 

  

	 	(ii)	the Products, if labelled and manufactured in accordance with the Specifications and in compliance with applicable cGMPs and Applicable Laws (i) may be lawfully sold and distributed in every jurisdiction in which
Client markets the Products, (ii) will be fit for the purpose intended, and (iii) will be safe for human consumption; 

  

	 	(iii)	on the date of shipment, the API will conform to the specifications for the API that Client has given to Patheon and that the API will be adequately contained, packaged, and labelled and will conform to the affirmations
of fact on the container. 

 9.3 Patheon Warranties. 

Patheon covenants, represents, and warrants that: 
  

	 	(a)	it will perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws; and 

  

	 	(b)	any Patheon Intellectual Property used by Patheon to perform the Manufacturing Services (i) is Patheon’s or its Affiliate’s unencumbered property, (ii) may be lawfully used by Patheon, and
(iii) does not infringe and will not infringe any Third Party Rights. 

 9.4 Debarred Persons. 

Patheon covenants that it will not in the performance of its obligations under this Agreement use the services of any person debarred or
suspended under 21 U.S.C. §335(a) or (b). Patheon represents that it does not currently have, and covenants that it will not hire, as an officer or an employee any person who has been convicted of a felony under the laws of the United States
for conduct relating to the regulation of any drug product under the Federal Food, Drug, and Cosmetic Act (United States). 

  
 - 25 - 

 Master Manufacturing Services Agreement 

 

 9.5 Permits. 

Client will be solely responsible for obtaining or maintaining, on a timely basis, any permits or other regulatory approvals for the Products
or the Specifications, including, without limitation, all marketing and post-marketing approvals. 
 Patheon will maintain at all relevant
times all governmental permits, licenses, approval, and authorities required to enable it to lawfully and properly perform the Manufacturing Services. 

9.6 No Warranty. 
 PATHEON
MAKES NO WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. PATHEON MAKES NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE NOR ANY WARRANTY OF MERCHANTABILITY FOR THE PRODUCTS.

 ARTICLE 10 

REMEDIES AND INDEMNITIES 
 10.1
Consequential Damages. 
 Under no circumstances whatsoever will either party be liable to the other in contract, tort,
negligence, breach of statutory duty, or otherwise for (i) any (direct or indirect) loss of profits, of production, of anticipated savings, of business, or goodwill or (ii) for any other liability, damage, costs, or expense of any kind
incurred by the other party of an indirect or consequential nature, regardless of any notice of the possibility of these damages. 
 10.2 Limitation of
Liability. 
 (a) Active Materials. Except as expressly set forth in Section 2.2, under no circumstances will
Patheon be responsible for any loss or damage to the Active Materials. Patheon’s maximum responsibility for loss or damage to the Active Materials will not exceed the Maximum Credit Value set forth in Schedule D of a Product Agreement. 

(b) Maximum Liability. Patheon’s maximum liability to Client under this Agreement or any Product Agreement for any reason
whatsoever, including, without limitation, any liability arising under Article 6 hereof or resulting from any and all breaches of its representations, warranties, or any other obligations under this Agreement or any Product Agreement, but excluding
[...***...], will not exceed on a per Product basis [...***...]% of revenues per Year to Patheon under the applicable Product Agreement, up to a maximum of $[...***...] in the aggregate per Year for all Products. 

10.3 Patheon. 
 Patheon
agrees to defend and indemnify Client, its officers, employees, and agents against all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates) resulting from, or relating to
any claim of personal injury or property damage to the extent that the injury or damage is the result of a failure by Patheon to perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws except to the
extent that the 

  
  

	***	Confidential Treatment Requested 

 - 26 - 

 Master Manufacturing Services Agreement 

 

 
losses, damages, costs, claims, demands, judgments, and liability are due to the negligence or wrongful act(s) of Client, its officers, employees, agents, or Affiliates. 

If a claim occurs, Client will: (a) promptly notify Patheon of the claim; (b) use commercially reasonable efforts to mitigate the
effects of the claim; (c) reasonably cooperate with Patheon in the defense of the claim; and (d) permit Patheon to control the defense and settlement of the claim, all at Patheon’s cost and expense. 

10.4 Client. 
 Client agrees
to defend and indemnify Patheon, its officers, employees, and agents against all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates) resulting from, or relating to any
claim of infringement or alleged infringement of any Third Party Rights in the Products, or any portion thereof, or any claim of personal injury or property damage to the extent that the injury or damage is the result of a breach of this Agreement
by Client, including, without limitation, any representation or warranty contained herein, except to the extent that the losses, damages, costs, claims, demands, judgments, and liability are due to the negligence or wrongful act(s) of Patheon, its
officers, employees, or agents. 
 If a claim occurs, Patheon will: (a) promptly notify Client of the claim; (b) use commercially
reasonable efforts to mitigate the effects of the claim; (c) reasonably cooperate with Client in the defense of the claim; and (d) permit Client to control the defense and settlement of the claim, all at Client’s cost and expense.

 10.5 Reasonable Allocation of Risk. 

This Agreement (including, without limitation, this Article 10) is reasonable and creates a reasonable allocation of risk for the relative
profits the parties each expect to derive from the Products. Patheon assumes only a limited degree of risk arising from the manufacture, distribution, and use of the Products because Client has developed and holds the marketing approval for the
Products, Client requires Patheon to manufacture and label the Products strictly in accordance with the Specifications, and Client, not Patheon, is best positioned to inform and advise potential users about the circumstances and manner of use of the
Products. 
 ARTICLE 11 

CONFIDENTIALITY 
 11.1
Confidentiality. 
 The Confidentiality Agreement will apply to all confidential information disclosed by the parties under
this Agreement or any Product Agreement. If the Confidentiality Agreement expires or is terminated prior to the expiration or termination of this Agreement or any Product Agreement, the terms of the Confidentiality Agreement will continue to govern
the parties’ obligations of confidentiality for any confidential or proprietary information disclosed by the parties hereunder, for the term of this Agreement or any Product Agreement, as though the Confidentiality Agreement remained in full
force and effect. 

  
 - 27 - 

 Master Manufacturing Services Agreement 

 

 ARTICLE 12 

DISPUTE RESOLUTION 
 12.1
Commercial Disputes. 
 If any dispute arises out of this Agreement or any Product Agreement (other than a dispute under
Section 6.1(b) or a Technical Dispute, as defined herein), the parties will first try to resolve it amicably. In that regard, any party may send a notice of dispute to the other, and each party will appoint, within [...***...] Business Days
from receipt of the notice of dispute, a single representative having full power and authority to resolve the dispute. The representatives will meet as necessary in order to resolve the dispute. If the representatives fail to resolve the matter
within [...***...] from their appointment, or if a party fails to appoint a representative within the [...***...] Business Day period set forth above, the dispute will immediately be referred to the Chief Operating Officer (or another
officer as he/she may designate) of each party who will meet and discuss as necessary to try to resolve the dispute amicably. Should the parties fail to reach a resolution under this Section 12.1, the dispute will be referred to a court of
competent jurisdiction in accordance with Section 13.16. 
 12.2 Technical Dispute Resolution. 

If a dispute arises (other than disputes under Sections 6.1(b) or 12.1) between the parties that is exclusively related to technical aspects of
the manufacturing, packaging, labelling, quality control testing, handling, storage, or other activities under this Agreement (a “Technical Dispute”), the parties will make all reasonable efforts to resolve the dispute by amicable
negotiations. In that regard, senior representatives of each party will, as soon as possible and in any event no later than [...***...] Business Days after a written request from either party to the other, meet in good faith to resolve any
Technical Dispute. If, despite this meeting, the parties are unable to resolve a Technical Dispute within a reasonable time, and in any event within [...***...] Business Days of the written request, the Technical Dispute will, at the request
of either party, be referred for determination to an expert in accordance with Exhibit A. If the parties cannot agree that a dispute is a Technical Dispute, Section 12.1 will prevail. For greater certainty, the parties agree that the release of
the Products for sale or distribution under the applicable marketing approval for the Products will not by itself indicate compliance by Patheon with its obligations for the Manufacturing Services and further that nothing in this Agreement
(including Exhibit A) will remove or limit the authority of the relevant qualified person (as specified by the Quality Agreement) to determine whether the Products are to be released for sale or distribution. 

ARTICLE 13 

MISCELLANEOUS 
 13.1
Corporate Responsibility. Patheon, while performing the Manufacturing Services under this Agreement, will comply, in all material respects, with all applicable laws, rules, regulations, and standards that relate to the Agreement
including, but not limited to, those relating to environmental matters, public health, wages, hours and conditions of employment, subcontractor selection, discrimination and occupational health/safety. Without limiting the foregoing, Patheon
covenants that neither Patheon nor any of its subcontractors will utilize child or any form of forced or involuntary labor in while performing the Manufacturing Services under this Agreement. Upon Client’s reasonable written request, Patheon
will certify in writing its compliance with this Section 13.1 and will provide copies of all applicable permits, certificates and licenses that may be required for its performance under this Agreement. Upon Client’s reasonable written
request, Patheon will allow Client or its authorized representatives to audit the Manufacturing Site to verify Patheon’s performance against the requirements 

  
  

	***	Confidential Treatment Requested 

 - 28 - 

 Master Manufacturing Services Agreement 

 

 
in this Section 13.1. This audit right does not include the right to interview any Patheon employee or subcontractor or to review any personnel or medical files of Patheon’s employees,
any Environmental, Health or Safety files of Patheon, any internal audit files of Patheon, or any financial records, including payroll records, of Patheon. Client will have the right to terminate this Agreement in whole or in part, as set forth in
Section 8.2(a), if Patheon fails to materially comply with the requirements of this Section 13.1. 
 13.2 Inventions. 

(a) For the term of this Agreement, Client hereby grants to Patheon a non-exclusive, paid-up, royalty-free, non-transferable license of
Client’s Intellectual Property which Patheon must use in order to perform the Manufacturing Services. 
 (b) All Intellectual Property
generated or derived by Patheon while performing the Manufacturing Services, to the extent it is specific to the development, manufacture, use, and sale of Client’s Product that is the subject of the Manufacturing Services, will be the
exclusive property of Client. 
 (c) All Patheon Intellectual Property will be the exclusive property of Patheon. Patheon hereby grants to
Client a perpetual, irrevocable, non-exclusive, paid-up, royalty-free, transferable license to use the Patheon Intellectual Property used by Patheon to perform the Manufacturing Services to enable Client to manufacture the Product(s). 

(d) Each party will be solely responsible for the costs of filing, prosecution, and maintenance of patents and patent applications on its own
Inventions. 
 (e) Either party will give the other party written notice, as promptly as practicable, of all Inventions which can reasonably
be deemed to constitute improvements or other modifications of the Products or processes or technology owned or otherwise controlled by the party. 
 13.3
Intellectual Property. 
 Subject to Section 13.1, all Client Intellectual Property will be owned by Client and all
Patheon Intellectual Property will be owned by Patheon. Neither party has, nor will it acquire, any interest in any of the other party’s Intellectual Property unless otherwise expressly agreed to in writing. Neither party will use any
Intellectual Property of the other party, except as specifically authorized by the other party or as required for the performance of its obligations under this Agreement. 

13.4 Insurance. 
 Each party
will maintain commercial general liability insurance, including blanket contractual liability insurance covering the obligations of that party under this Agreement through the term of this Agreement and for a period of three years thereafter. This
insurance will have policy limits of not less than (i) $[...***...] for each occurrence for personal injury or property damage liability; and (ii) $[...***...] in the aggregate per annum for product and completed operations
liability. If requested each party will give the other a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date, and the limits of liability. The
insurance certificate will further provide for a minimum of [...***...] days’ written notice to the insured of a cancellation of, or material change in, the insurance. If a party is unable to maintain the insurance policies required under
this Agreement through no fault of its own, then the party will forthwith notify the other party in writing and the parties will in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate
assurances. 

  
  

	***	Confidential Treatment Requested 

 - 29 - 

 Master Manufacturing Services Agreement 

 

 13.5 Independent Contractors. 

The parties are independent contractors and this Agreement and any Product Agreement will not be construed to create between Patheon and Client
any other relationship such as, by way of example only, that of employer-employee, principal agent, joint-venturer, co-partners, or any similar relationship, the existence of which is expressly denied by the parties. 

13.6 No Waiver. 
 Either
party’s failure to require the other party to comply with any provision of this Agreement or any Product Agreement will not be deemed a waiver of the provision or any other provision of this Agreement or any Product Agreement, with the
exception of Sections 6.1 and 8.2 of this Agreement. 
 13.7 Assignment. 

 

	 	(a)	Patheon may not assign this Agreement or any Product Agreement or any of its associated rights or obligations without the written consent of Client, this consent not to be unreasonably withheld. But Patheon may arrange
for subcontractors to perform specific testing services arising under any Product Agreement without the consent of Client. Further it is specifically agreed that Patheon may subcontract any part of the Manufacturing Services under a Product
Agreement to any of its Affiliates with Client’s written consent, this consent not to be unreasonably withheld. 

  

	 	(b)	Subject to Section 8.2(d), Client may assign this Agreement or any Product Agreement or any of its associated rights or obligations without approval from Patheon. But Client will give Patheon prior written notice
of any assignment, any assignee will covenant in writing with Patheon to be bound by the terms of this Agreement or the Product Agreement, and Client will remain liable hereunder. Any partial assignment will be subject to Patheon’s cost review
of the assigned Products and Patheon may terminate this Agreement or any Product Agreement or any assigned part thereof, on [...***...] months’ prior written notice to Client and the assignee if good faith discussions do not lead to agreement
on amended Manufacturing Service fees within a reasonable time. 

  

	 	(c)	Despite the foregoing provisions of this Section 13.6, either party may assign this Agreement or any Product Agreement to any of its Affiliates or to a successor to or purchaser of all or substantially all of its
business, but the assignee must execute an agreement with the non-assigning party whereby it agrees to be bound hereunder. 

 13.8 Force
Majeure. 
 Neither party will be liable for the failure to perform its obligations under this Agreement or any Product
Agreement if the failure is caused by an event beyond that party’s reasonable control, including, but not limited to, strikes or other labor disturbances, lockouts, riots, quarantines, communicable disease outbreaks, wars, acts of terrorism,
fires, floods, storms, interruption of or delay in transportation, defective equipment, lack of or inability to obtain fuel, power or components, or compliance with any order or regulation of any government entity acting within colour of right (a
“Force Majeure Event”). A party claiming a right to excused performance under this Section 13.7 will immediately notify the other party in writing of the extent of its inability to perform, which notice will specify the event
beyond its reasonable control that prevents the performance. Neither party will be entitled to rely on a Force Majeure Event to relieve it from an obligation to pay money (including any interest for 

  
  

	***	Confidential Treatment Requested 

 - 30 - 

 Master Manufacturing Services Agreement 

 

 
delayed payment) which would otherwise be due and payable under this Agreement or any Product Agreement. 

13.9 Additional Product. 

Additional Products may be added to, or existing Products deleted from, any Product Agreement by amendments to the Product Agreement including
Schedules A, B, C, and D as applicable. 
 13.10 Notices. 

Unless otherwise agreed in a Product Agreement, any notice, approval, instruction or other written communication required or permitted
hereunder will be sufficient if made or given to the other party by personal delivery, by telecopy, facsimile communication, or confirmed receipt email or by sending the same by first class mail, postage prepaid to the respective addresses, telecopy
or facsimile numbers or electronic mail addresses set forth below: 
 If to Client: 

Horizon Pharm Inc. 
 520 Lake Cook
Road Suite 520 
 Deerfield, IL 60015 

Attention: Jeff Sherman 

Telecopier No.: (224) 383-3001 

Email address: JSherman@horizonpharma.com 

With a copy to: 
 Horizon Pharm
Inc. 
 520 Lake Cook Road Suite 520 

Deerfield, IL 60015 
 Attention:
Brian Beeler 
 Telecopier No.: (224) 383-3001 

Email address: BBeeler@horizonpharma.com 

If to Patheon: 
 Patheon
Pharmaceuticals Inc 
 2110 East Galbraith Road 

Cincinnati, OH 45237-1625 

Attention: [...***...] 

Telecopier No.: [...***...] 

Email address: [...***...] 
 With
a copy to: 
 Patheon Inc. 

4721 Emperor Boulevard 
 Research
Triangle Park, 
 NC 27703 

  
  

	***	Confidential Treatment Requested 

 - 31 - 

 Master Manufacturing Services Agreement 

 

 given by personal delivery, telecopy, facsimile, or electronic mail will be deemed to have been sufficiently
made or given when sent (receipt acknowledged), or if mailed, five days after being deposited in the United States, Canada, or European Union mail, postage prepaid or upon receipt, whichever is sooner. 

13.11 Severability. 
 If any
provision of this Agreement or any Product Agreement is determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, that determination will not impair or affect the validity, legality, or enforceability
of the remaining provisions, because each provision is separate, severable, and distinct. 
 13.12 Entire Agreement. 

This Agreement, together with the applicable Product Agreement, Quality Agreement and the Confidentiality Agreement, constitutes the full,
complete, final and integrated agreement between the parties relating to the subject matter hereof and supersedes all previous written or oral negotiations, commitments, agreements, transactions, or understandings concerning the subject matter
hereof. Any modification, amendment, or supplement to this Agreement or any Product Agreement must be in writing and signed by authorized representatives of both parties. In case of conflict, the prevailing order of documents will be this Agreement,
the Product Agreement, the Quality Agreement, and the Confidentiality Agreement. 
 13.13 Other Terms. 

No terms, provisions or conditions of any purchase order or other business form or written authorization used by Client or Patheon will have
any effect on the rights, duties, or obligations of the parties under or otherwise modify this Agreement or any Product Agreement, regardless of any failure of Client or Patheon to object to the terms, provisions, or conditions unless the document
specifically refers to this Agreement or the applicable Product Agreement and is signed by both parties. 
 13.14 No Third Party Benefit or
Right. 
 For greater certainty, nothing in this Agreement or any Product Agreement will confer or be construed as conferring
on any third party any benefit or the right to enforce any express or implied term of this Agreement or any Product Agreement. 
 13.15 Execution in
Counterparts. 
 This Agreement and any Product Agreement may be executed in two or more counterparts, by original or
facsimile signature, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 
 13.16 Use of
Client Name. 
 Patheon will not make any use of Client’s name, trademarks or logo or any variations thereof, alone or
with any other word or words, without the prior written consent of Client, which consent will not be unreasonably withheld. Despite this, Client agrees that Patheon may include Client’s name and logo in customer lists or related marketing
and promotional material for the purpose of identifying users of Patheon’s Manufacturing Services.

  
 - 32 - 

 Master Manufacturing Services Agreement 

 

 13.17 Governing Law. 

This Agreement and, unless otherwise agreed by the parties, any Product Agreement, will be construed and enforced in accordance with the laws
of the State of New York and the laws of the United States of America applicable therein and subject to the exclusive jurisdiction of the courts thereof. The UN Convention on Contracts for the International Sale of Goods will not apply to this
Agreement. 
 [Signature page to follow] 

  
 - 33 - 

 Master Manufacturing Services Agreement 

 

 IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this
Agreement as of the Effective Date. 
  

			
	PATHEON PHARMACEUTICALS INC.
		
	By:	 	/s/ Dean Wilson
	Name:	 	Dean Wilson
	Title:	 	Corporate Controller
	
	HORIZON PHARMA INC.
		
	By:	 	/s/ Jeffrey W. Sherman
	Name:	 	Jeffrey W. Sherman, M.D., FACP
	Title:	 	Chief Medical Officer, EVP
	
	HORIZON PHARMA INC.
		
	By:	 	/s/ Todd N. Smith
	Name:	 	Todd N. Smith
	Title:	 	CCO, EVP

  
 - 34 - 

 Master Manufacturing Services Agreement 

 

 APPENDIX 1 

FORM OF PRODUCT AGREEMENT 

(Includes Schedules A to D) 

PRODUCT AGREEMENT 

This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement
dated October 31, 2013 between Patheon Pharmaceuticals Inc., and Horizon Pharma Inc., (the “Master Agreement”), and is entered into [insert effective date] (the “Effective Date”), between Patheon
Pharmaceuticals Inc., [or applicable Patheon Affiliate], a corporation existing under the laws of the State of Delaware [or applicable founding jurisdiction for Patheon Affiliate], having a principal place of business at 2110 East
Galbraith Road, Cincinnati, OH 45237-1625 [or Patheon Affiliate address] (“Patheon”) and [insert Client name, legal entity, founding jurisdiction and address] (“Client”). 

The terms and conditions of the Master Agreement are incorporated herein except to the extent this Product Agreement expressly
references the specific provision in the Master Agreement to be modified by this Product Agreement. All capitalized terms that are used but not defined in this Product Agreement will have the respective meanings given to them in the Master
Agreement. 
 The Schedules to this Product Agreement are incorporated into and will be construed in accordance with the
terms of this Product Agreement. 
  

	 	1.	Product List and Specifications (See Schedule A attached hereto) 

  

	 	2.	Minimum Order Quantity, Annual Volume, and Price (See Schedule B attached hereto) 

  

	 	3.	Annual Stability Testing and Validation Activities (if applicable) (See Schedule C attached hereto) 

  

	 	4.	Active Materials, Active Materials Credit Value, and Maximum Credit Value (See Schedule D attached hereto) 

  

	 	5.	Yearly Forecasted Volume: (insert for sterile products in Italy if applicable under section 4.2.1) 

  

	 	6.	Territory: (insert the description of the Territory here) 

  

	 	7.	Manufacturing Site: (insert address of Patheon Manufacturing Site where the Manufacturing Services will be performed) 

  

	 	8.	Governing Law: (if applicable under Section 13.16 of the Master Agreement) 

  

	 	9.	Inflation Index: (if applicable under Section 4.2(a) of the Master Agreement for Products manufactured outside of the Unites States or Puerto Rico) 

 

	 	10.	Currency: (if applicable under Section 1.4 of the Master Agreement) 

  
 - 1 - 

 Master Manufacturing Services Agreement 

 

	 	11.	Initial Set Exchange Rate: (if applicable under Section 4.2(d) of the Master Agreement) 

  

	 	12.	Initial Product Term: (if applicable under Section 8.1 of the Master Agreement) 

  

	 	13.	Notices: (if applicable under Section 13.9 of the Master Agreement) 

  

	 	14.	Other Modifications to the Master Agreement: (if applicable under Section 1.2 of the Master Agreement) 

  

 

IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this Product Agreement as of the
Effective Date set forth above. 
  

			
	PATHEON PHARMACEUTICALS INC. [or applicable Patheon Affiliate]
		
	By:	 	 
	Name:	 	 
	Title:	 	 
	
	HORIZON PHARMA INC. [or applicable Horizon Affiliate]
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 

 SCHEDULE A 

PRODUCT LIST AND SPECIFICATIONS 

[...***...] 

  
  

	***	Confidential Treatment Requested 

 - 3 - 

 Master Manufacturing Services Agreement 

 

 SCHEDULE B 

MINIMUM ORDER QUANTITY, ANNUAL VOLUME, AND PRICE 

[...***...] 

  
  

	***	Confidential Treatment Requested 

 - 1 - 

 Master Manufacturing Services Agreement 

 

 SCHEDULE C 

ANNUAL STABILITY TESTING [and VALIDATION ACTIVITIES (if applicable)] 

[...***...] 

  
  

	***	Confidential Treatment Requested 

 - 1 - 

 Master Manufacturing Services Agreement 

 

 SCHEDULE D 

ACTIVE MATERIALS 
  

			
	 Active Materials
	 	 Supplier

	—	 	—
	—	 	—

 ACTIVE MATERIALS CREDIT VALUE 

The Active Materials Credit Value will be as follows: 
  

					
	 PRODUCT
	  	 ACTIVE MATERIALS
	  	 ACTIVE MATERIALS

CREDIT VALUE

		  		  	[...***...]

 MAXIMUM CREDIT VALUE 

Patheon’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will
not exceed, in the aggregate, the maximum credit value set forth below: 
  

			
	 PRODUCT
	  	 MAXIMUM CREDIT VALUE

		  	[    ]% of revenues per Year to Patheon under this Product Agreement, up to a maximum of $[            ] in the aggregate per
Year.

 [End of Product Agreement] 

  
  

	***	Confidential Treatment Requested 

 - 1 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT A 

TECHNICAL DISPUTE RESOLUTION 

Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 will be resolved in the following manner: 

1. Appointment of Expert. Within [...***...] Business Days after a party requests under Section 12.2 that an expert be appointed to resolve
a Technical Dispute, the parties will jointly appoint a mutually acceptable expert with experience and expertise in the subject matter of the dispute. If the parties are unable to so agree within the [...***...] Business Day period, or in the
event of disclosure of a conflict by an expert under Paragraph 2 hereof which results in the parties not confirming the appointment of the expert, then an expert (willing to act in that capacity hereunder) will be appointed by an experienced
arbitrator on the roster of the American Arbitration Association. 
 2. Conflicts of Interest. Any person appointed as an expert will be
entitled to act and continue to act as an expert even if at the time of his appointment or at any time before he gives his determination, he has or may have some interest or duty which conflicts or may conflict with his appointment if before
accepting the appointment (or as soon as practicable after he becomes aware of the conflict or potential conflict) he fully discloses the interest or duty and the parties will, after the disclosure, have confirmed his appointment. 

3. Not Arbitrator. No expert will be deemed to be an arbitrator and the provisions of the American Arbitration Act or of any other applicable
statute (foreign or domestic) and the law relating to arbitration will not apply to the expert or the expert’s determination or the procedure by which the expert reaches his determination under this Exhibit A. 

4. Procedure. Where an expert is appointed: 
  

	 	(a)	Timing. The expert will be so appointed on condition that (i) he promptly fixes a reasonable time and place for receiving representations, submissions or information from the parties and that he issues the
authorizations to the parties and any relevant third party for the proper conduct of his determination and any hearing and (ii) he renders his decision (with full reasons) within [...***...] Business Days (or another other date as the
parties and the expert may agree) after receipt of all information requested by him under Paragraph 4(b) hereof. 

  

	 	(b)	Disclosure of Evidence. The parties undertake one to the other to give to any expert all the evidence and information within their respective possession or control as the expert may reasonably consider necessary
for determining the matter before him which they will disclose promptly and in any event within [...***...] Business Days of a written request from the relevant expert to do so. 

 

	 	(c)	Advisors. Each party may appoint any counsel, consultants and advisors as it feels appropriate to assist the expert in his determination and so as to present their respective cases so that at all times the
parties will co-operate and seek to narrow and limit the issues to be determined. 

  

	 	(d)	Appointment of New Expert. If within the time specified in Paragraph 4(a) above the expert will not have rendered a decision in accordance with his appointment, a new expert may (at the request of either party)
be appointed and the appointment of the 

  
  

	***	Confidential Treatment Requested 

 - 1 - 

 Master Manufacturing Services Agreement 

 

	 	
existing expert will thereupon cease for the purposes of determining the matter at issue between the parties save this if the existing expert renders his decision with full reasons prior to the
appointment of the new expert, then this decision will have effect and the proposed appointment of the new expert will be withdrawn. 

  

	 	(e)	Final and Binding. The determination of the expert will, except for fraud or manifest error, be final and binding upon the parties. 

 

	 	(f)	Costs. Each party will bear its own costs for any matter referred to an expert hereunder and, in the absence of express provision in the Agreement to the contrary, the costs and expenses of the expert will be
shared equally by the parties. 

 For greater certainty, the release of the Products for sale or distribution under the applicable marketing
approval for the Products will not by itself indicate compliance by Patheon with its obligations for the Manufacturing Services and further that nothing in this Agreement (including this Exhibit A) will remove or limit the authority of the relevant
qualified person (as specified by the Quality Agreement) to determine whether the Products are to be released for sale or distribution. 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT B 

COMMERCIAL QUALITY AGREEMENT 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT C 

QUARTERLY ACTIVE MATERIALS INVENTORY REPORT 
  

	TO:	HORIZON PHARMA INC 

  

	FROM:	PATHEON PHARMACEUTICALS INC. [or applicable Patheon entity] 

  

	RE:	Active Materials quarterly inventory report under Section 2.2(a) of the Master Manufacturing Services Agreement dated October 31, 2013 (the “Agreement”) 

[...***...] 

  
  

	***	Confidential Treatment Requested 

 - 2 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT D 

REPORT OF ANNUAL ACTIVE MATERIALS INVENTORY RECONCILIATION 

AND CALCULATION OF ACTUAL ANNUAL YIELD 
  

			
	TO:	  	HORIZON PHARMA INC.
		
	FROM:	  	PATHEON PHARMACEUTICALS INC. [or applicable Patheon entity]
		
	RE:	  	Active Materials annual inventory reconciliation report and calculation of Actual Annual Yield under Section 2.2(a) of the Master Manufacturing Services Agreement dated October 31, 2013 (the “Agreement”)

 [...***...] 

  
  

	***	Confidential Treatment Requested 

 - 2 - 

 Master Manufacturing Services Agreement 

 

 [...***...] 

Based on the foregoing reimbursement calculation Patheon will reimburse Client the amount of
$            . 
 Capitalized terms used in this report have the meanings given to the terms in
the Agreement. 
  

			
	DATE:                             
	
	 PATHEON PHARMACEUTICALS INC.

	 [or applicable Patheon entity]

		
	Per:	 	 
	 Name:
	 	
	 Title:
	 	

  
  

	***	Confidential Treatment Requested 

 - 2 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT E 

EXAMPLE OF PRICE ADJUSTMENT DUE TO CURRENCY FLUCTUATION 

Section 4.2(d) 
  

 

  
 - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]